Heterogeneity	O
of	O
the	O
in	O
vitro	O
responses	O
to	O
glucocorticoids	O
in	O
acute	O
leukemia	O
.	O

In	O
leukocyte	B-cell_type
population	I-cell_type
freshly	O
isolated	O
from	O
the	O
blood	O
of	O
26	O
patients	O
with	O
acute	O
leukemia	O
,	O
we	O
have	O
measured	O
several	O
parameters	O
including	O
glucocorticoid	B-protein
receptors	I-protein
,	O
nucleoside	O
incorporation	O
,	O
percentage	O
of	O
cells	O
in	O
S	O
phase	O
,	O
and	O
steroid-induced	O
cell	O
lysis	O
.	O

In	O
addition	O
,	O
in	O
some	O
cases	O
,	O
the	O
short-term	O
response	O
to	O
steroid	O
therapy	O
was	O
determined	O
.	O

Although	O
,	O
in	O
all	O
the	O
patients	O
studied	O
,	O
leukocytes	B-cell_type
were	O
found	O
to	O
contain	O
glucocorticoid	B-protein
receptors	I-protein
,	O
we	O
failed	O
to	O
demonstrate	O
any	O
correlation	O
between	O
the	O
level	O
of	O
binding	O
sites	O
and	O
the	O
in	O
vitro	O
or	O
in	O
vivo	O
response	O
to	O
glucocorticoids	O
.	O

This	O
absence	O
of	O
correlation	O
could	O
be	O
in	O
part	O
explained	O
by	O
the	O
marked	O
heterogeneity	O
of	O
the	O
steroid	O
response	O
demonstrated	O
in	O
leukocyte	O
subpopulations	O
.	O

It	O
appears	O
,	O
however	O
,	O
that	O
the	O
degree	O
of	O
steroid	O
action	O
in	O
vitro	O
as	O
well	O
as	O
the	O
extent	O
of	O
spontaneous	O
and	O
dexamethasone-induced	O
cell	O
death	O
may	O
be	O
related	O
to	O
the	O
number	O
of	O
cells	O
in	O
the	O
S	O
phase	O
of	O
the	O
cell	O
cycle	O
.	O

[	NULL
CANCER	NULL
RESEARCH	NULL
40	NULL
,	NULL
2601-2608	NULL
,	NULL
July	NULL
1980	NULL
]	NULL
0008-5472/80/0040-0000	NULL
$	NULL
02.00	NULL
Heterogeneity	NULL
of	NULL
the	NULL
in	NULL
Vitro	NULL
Responses	NULL
to	NULL
Glucocorticoids	NULL
in	NULL
Acute	NULL
Leukemia	NULL
F.	NULL
Homo	NULL
,	NULL
D.	NULL
Duval	NULL
,	NULL
J.	NULL
L.	NULL
Harousseau	NULL
,	NULL
J.	NULL
P.	NULL
Marie	NULL
,	NULL
and	NULL
R.	NULL
Zittoun	NULL
Physiologie	NULL
et	NULL
Pharmacologie	NULL
,	NULL
INSERM	NULL
U7	NULL
,	NULL
Hopital	NULL
Necker	NULL
,	NULL
161	NULL
rue	NULL
de	NULL
Sévres	NULL
,	NULL
75730	NULL
Paris	NULL
Cédex	NULL
15	NULL
[	NULL
F.	NULL
H.	NULL
,	NULL
D.	NULL
D.	NULL
}	NULL
;	NULL
Service	NULL
d'Hématologie	NULL
,	NULL
Hopital	NULL
Saint	NULL
Louis	NULL
,	NULL
2	NULL
place	NULL
du	NULL
Dr.	NULL
Fournier	NULL
,	NULL
75475	NULL
Paris	NULL
Cédex	NULL
10	NULL
[	NULL
J.	NULL
L.	NULL
H.	NULL
}	NULL
;	NULL
and	NULL
Service	NULL
d'Hématologie	NULL
,	NULL
Hotel	NULL
Dieu	NULL
,	NULL
Place	NULL
du	NULL
Parvus	NULL
Notre	NULL
Dame	NULL
,	NULL
75004	NULL
Paris	NULL
[	NULL
J.	NULL
P.	NULL
M.	NULL
,	NULL
R	NULL
.	NULL

Z	NULL
.	NULL
]	NULL

,	NULL
France	NULL
ABSTRACT	NULL
In	NULL
leukocyte	NULL
populations	NULL
freshly	NULL
isolated	NULL
from	NULL
the	NULL
blood	NULL
of	NULL
26	NULL
patients	NULL
with	NULL
acute	NULL
leukemia	NULL
,	NULL
we	NULL
have	NULL
measured	NULL
several	NULL
parameters	NULL
including	NULL
glucocorticoid	NULL
receptors	NULL
,	NULL
nucleoside	NULL
incorporation	NULL
,	NULL
percentage	NULL
of	NULL
cells	NULL
in	NULL
S	NULL
phase	NULL
,	NULL
and	NULL
steroid-induced	NULL
cell	NULL
lysis	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
in	NULL
some	NULL
cases	NULL
,	NULL
the	NULL
short-term	NULL
response	NULL
to	NULL
steroid	NULL
therapy	NULL
was	NULL
determined	NULL
.	NULL

Although	NULL
,	NULL
in	NULL
all	NULL
the	NULL
patients	NULL
studied	NULL
,	NULL
leukocytes	NULL
were	NULL
found	NULL
to	NULL
contain	NULL
glucocorticoid	NULL
receptors	NULL
,	NULL
we	NULL
failed	NULL
to	NULL
demonstrate	NULL
any	NULL
correlation	NULL
between	NULL
the	NULL
level	NULL
of	NULL
binding	NULL
sites	NULL
and	NULL
the	NULL
in	NULL
vitro	NULL
or	NULL
in	NULL
vivo	NULL
response	NULL
to	NULL
glucocorticoids	NULL
.	NULL

This	NULL
absence	NULL
of	NULL
correlation	NULL
could	NULL
be	NULL
in	NULL
part	NULL
explained	NULL
by	NULL
the	NULL
marked	NULL
heterogeneity	NULL
of	NULL
the	NULL
steroid	NULL
response	NULL
demonstrated	NULL
in	NULL
leukocyte	NULL
subpopulations	NULL
.	NULL

It	NULL
appears	NULL
,	NULL
however	NULL
,	NULL
that	NULL
the	NULL
degree	NULL
of	NULL
steroid	NULL
action	NULL
in	NULL
vitro	NULL
as	NULL
well	NULL
as	NULL
the	NULL
extent	NULL
of	NULL
spontaneous	NULL
and	NULL
dexamethasone-induced	NULL
cell	NULL
death	NULL
may	NULL
be	NULL
related	NULL
to	NULL
the	NULL
number	NULL
of	NULL
cells	NULL
in	NULL
the	NULL
S	NULL
phase	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
.	NULL

INTRODUCTION	NULL
It	NULL
is	NULL
now	NULL
widely	NULL
accepted	NULL
that	NULL
ALL	NULL
'	NULL
is	NULL
a	NULL
heterogeneous	NULL
disease	NULL
with	NULL
regard	NULL
to	NULL
its	NULL
clinical	NULL
aspects	NULL
,	NULL
its	NULL
response	NULL
to	NULL
chemotherapy	NULL
,	NULL
and	NULL
its	NULL
prognosis	NULL
(	NULL
1	NULL
,	NULL
3	NULL
,	NULL
4	NULL
,	NULL
7	NULL
,	NULL
8	NULL
,	NULL
12	NULL
,	NULL
41	NULL
,	NULL
47	NULL
)	NULL
.	NULL

It	NULL
has	NULL
been	NULL
shown	NULL
that	NULL
the	NULL
clinical	NULL
heterogeneity	NULL
of	NULL
ALL	NULL
appears	NULL
in	NULL
part	NULL
to	NULL
be	NULL
related	NULL
to	NULL
the	NULL
extent	NULL
of	NULL
lymphocyte	NULL
differentiation	NULL
,	NULL
a	NULL
high	NULL
proportion	NULL
of	NULL
cases	NULL
arising	NULL
from	NULL
bone	NULL
marrow-derived	NULL
``	NULL
null	NULL
``	NULL
cells	NULL
and	NULL
the	NULL
rest	NULL
from	NULL
cells	NULL
differentiating	NULL
into	NULL
mature	NULL
T-	NULL
and	NULL
B-cells	NULL
.	NULL

More	NULL
recently	NULL
,	NULL
these	NULL
3	NULL
main	NULL
groups	NULL
have	NULL
been	NULL
subdivided	NULL
according	NULL
to	NULL
the	NULL
level	NULL
of	NULL
leukemic	NULL
cell	NULL
differentiation	NULL
,	NULL
based	NULL
on	NULL
the	NULL
study	NULL
of	NULL
constitutive	NULL
enzymes	NULL
and	NULL
other	NULL
biochemical	NULL
markers	NULL
.	NULL

This	NULL
immunological	NULL
classification	NULL
is	NULL
of	NULL
practical	NULL
value	NULL
,	NULL
since	NULL
correlations	NULL
have	NULL
been	NULL
demonstrated	NULL
between	NULL
the	NULL
phenotype	NULL
of	NULL
the	NULL
leukemic	NULL
cells	NULL
and	NULL
the	NULL
prognosis	NULL
of	NULL
the	NULL
disease	NULL
.	NULL

Because	NULL
of	NULL
the	NULL
well-known	NULL
catabolic	NULL
effects	NULL
of	NULL
glucocorticoids	NULL
on	NULL
lymphoid	NULL
tissue	NULL
(	NULL
9	NULL
,	NULL
36	NULL
)	NULL
,	NULL
glucocorticoids	NULL
have	NULL
been	NULL
used	NULL
for	NULL
more	NULL
than	NULL
20	NULL
years	NULL
in	NULL
the	NULL
treatment	NULL
of	NULL
leukemia	NULL
,	NULL
first	NULL
alone	NULL
and	NULL
now	NULL
as	NULL
a	NULL
part	NULL
of	NULL
combined	NULL
chemotherapy	NULL
(	NULL
3	NULL
,	NULL
4	NULL
,	NULL
31	NULL
)	NULL
.	NULL

It	NULL
appears	NULL
,	NULL
however	NULL
,	NULL
that	NULL
some	NULL
patients	NULL
are	NULL
resistant	NULL
to	NULL
steroid	NULL
treatment	NULL
or	NULL
cease	NULL
to	NULL
respond	NULL
over	NULL
the	NULL
course	NULL
of	NULL
the	NULL
treatment	NULL
.	NULL

Because	NULL
of	NULL
the	NULL
iatrogenic	NULL
complications	NULL
of	NULL
steroid	NULL
treatment	NULL
,	NULL
it	NULL
would	NULL
be	NULL
of	NULL
value	NULL
if	NULL
one	NULL
could	NULL
select	NULL
in	NULL
advance	NULL
those	NULL
patients	NULL
who	NULL
are	NULL
likely	NULL
to	NULL
respond	NULL
to	NULL
glucocorticoids	NULL
.	NULL

According	NULL
to	NULL
the	NULL
classical	NULL
mechanism	NULL
of	NULL
steroid	NULL
hormone	NULL
action	NULL
,	NULL
which	NULL
includes	NULL
a	NULL
preliminary	NULL
step	NULL
of	NULL
interaction	NULL
of	NULL
the	NULL
steroid	NULL
with	NULL
cytoplasmic	NULL
receptors	NULL
(	NULL
16	NULL
)	NULL
,	NULL
numerous	NULL
studies	NULL
have	NULL
*	NULL
The	NULL
abbreviations	NULL
used	NULL
are	NULL
:	NULL
ALL	NULL
,	NULL
acute	NULL
lymphocytic	NULL
leukemia	NULL
;	NULL
BSA	NULL
,	NULL
bovine	NULL
serum	NULL
albumin	NULL
;	NULL
HBSS	NULL
,	NULL
Hanks	NULL
'	NULL
balanced	NULL
salt	NULL
solution	NULL
;	NULL
GIBCO	NULL
,	NULL
Grand	NULL
Island	NULL
Biological	NULL
Co	NULL
.	NULL

Received	NULL
May	NULL
22	NULL
,	NULL
1979	NULL
;	NULL
accepted	NULL
April	NULL
15	NULL
,	NULL
1980	NULL
.	NULL

JULY	NULL
1980	NULL
been	NULL
devoted	NULL
to	NULL
the	NULL
question	NULL
of	NULL
whether	NULL
or	NULL
not	NULL
the	NULL
receptor	NULL
content	NULL
of	NULL
leukemic	NULL
cells	NULL
is	NULL
representative	NULL
of	NULL
their	NULL
in	NULL
vitro	NULL
or	NULL
in	NULL
vivo	NULL
steroid	NULL
sensitivity	NULL
and	NULL
would	NULL
therefore	NULL
be	NULL
indicative	NULL
of	NULL
therapy	NULL
(	NULL
5	NULL
,	NULL
11	NULL
,	NULL
14	NULL
,	NULL
23	NULL
,	NULL
24	NULL
,	NULL
28	NULL
,	NULL
30-33	NULL
,	NULL
46	NULL
)	NULL
.	NULL

The	NULL
situation	NULL
,	NULL
however	NULL
,	NULL
remains	NULL
unclear	NULL
.	NULL

Lippman	NULL
et	NULL
al	NULL
.	NULL

(	NULL
30	NULL
)	NULL
first	NULL
presented	NULL
evidence	NULL
in	NULL
favor	NULL
of	NULL
such	NULL
a	NULL
correlation	NULL
between	NULL
cytosolic	NULL
receptor	NULL
content	NULL
and	NULL
in	NULL
vitro	NULL
sensitivity	NULL
in	NULL
patients	NULL
with	NULL
ALL	NULL
.	NULL

Sibley	NULL
and	NULL
Tomkins	NULL
(	NULL
44	NULL
)	NULL
and	NULL
Lippman	NULL
et	NULL
al	NULL
.	NULL

(	NULL
32	NULL
)	NULL
later	NULL
described	NULL
the	NULL
existence	NULL
of	NULL
corticoresistant	NULL
lymphoma	NULL
or	NULL
lymphoblastoid	NULL
cell	NULL
lines	NULL
which	NULL
contained	NULL
glucocorticoid	NULL
receptors	NULL
.	NULL

Furthermore	NULL
,	NULL
Bird	NULL
et	NULL
al	NULL
.	NULL

(	NULL
5	NULL
)	NULL
,	NULL
as	NULL
well	NULL
as	NULL
Crabtree	NULL
et	NULL
al	NULL
.	NULL

(	NULL
11	NULL
)	NULL
,	NULL
Homo	NULL
et	NULL
al	NULL
.	NULL

(	NULL
24	NULL
)	NULL
,	NULL
and	NULL
Sioman	NULL
and	NULL
Bell	NULL
(	NULL
45	NULL
)	NULL
failed	NULL
to	NULL
demonstrate	NULL
any	NULL
significant	NULL
correlation	NULL
between	NULL
the	NULL
number	NULL
of	NULL
steroid	NULL
receptors	NULL
and	NULL
the	NULL
in	NULL
vitro	NULL
sensitivity	NULL
of	NULL
human	NULL
lymphoblastoid	NULL
cell	NULL
lines	NULL
or	NULL
human	NULL
leukemic	NULL
cells	NULL
.	NULL

In	NULL
this	NULL
study	NULL
,	NULL
we	NULL
have	NULL
measured	NULL
in	NULL
26	NULL
patients	NULL
with	NULL
acute	NULL
leukemia	NULL
not	NULL
only	NULL
the	NULL
level	NULL
of	NULL
glucocorticoid	NULL
receptor	NULL
and	NULL
later	NULL
steps	NULL
in	NULL
the	NULL
steroid	NULL
action	NULL
(	NULL
i.e	NULL
.	NULL

,	NULL
inhibition	NULL
of	NULL
nucleic	NULL
acid	NULL
precursors	NULL
and	NULL
cell	NULL
lysis	NULL
)	NULL
but	NULL
also	NULL
several	NULL
parameters	NULL
of	NULL
population	NULL
diversity	NULL
(	NULL
immunological	NULL
markers	NULL
,	NULL
morphology	NULL
,	NULL
pulse	NULL
cytophotometric	NULL
analysis	NULL
)	NULL
on	NULL
the	NULL
whole-leukocyte	NULL
populations	NULL
or	NULL
in	NULL
subpopulations	NULL
isolated	NULL
by	NULL
centrifugation	NULL
on	NULL
a	NULL
discontinued	NULL
BSA	NULL
gradient	NULL
.	NULL

In	NULL
some	NULL
cases	NULL
,	NULL
we	NULL
have	NULL
also	NULL
attempted	NULL
to	NULL
relate	NULL
these	NULL
parameters	NULL
to	NULL
the	NULL
short-term	NULL
in	NULL
vivo	NULL
response	NULL
to	NULL
glucocorticoid	NULL
therapy	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Patients	NULL
.	NULL

Studies	NULL
were	NULL
performed	NULL
in	NULL
26	NULL
patients	NULL
with	NULL
acute	NULL
leukemia	NULL
,	NULL
comprising	NULL
24	NULL
patients	NULL
with	NULL
ALL	NULL
and	NULL
2	NULL
patients	NULL
with	NULL
chronic	NULL
myelocytic	NULL
leukemia	NULL
in	NULL
``	NULL
lymphoid	NULL
``	NULL
blast	NULL
crisis	NULL
.	NULL

In	NULL
each	NULL
of	NULL
the	NULL
patients	NULL
studied	NULL
,	NULL
cytological	NULL
examinations	NULL
were	NULL
performed	NULL
.	NULL

Blood	NULL
and	NULL
bone	NULL
marrow	NULL
were	NULL
stained	NULL
by	NULL
different	NULL
methods	NULL
including	NULL
May-Griuinwald-Giemsa	NULL
,	NULL
periodic	NULL
acid-Schiff	NULL
,	NULL
peroxidase	NULL
,	NULL
and	NULL
also	NULL
,	NULL
in	NULL
numerous	NULL
cases	NULL
,	NULL
by	NULL
an	NULL
acid	NULL
phosphatase	NULL
reagent	NULL
.	NULL

Detection	NULL
of	NULL
T-cells	NULL
was	NULL
performed	NULL
by	NULL
the	NULL
erythrocyte	NULL
rosette-forming	NULL
test	NULL
using	NULL
sheep	NULL
erythrocytes	NULL
and	NULL
by	NULL
the	NULL
trypan	NULL
blue	NULL
dye	NULL
exclusion	NULL
test	NULL
with	NULL
a	NULL
rabbit	NULL
anti-human	NULL
T-lymphocyte	NULL
antiserum	NULL
(	NULL
Merieux	NULL
Institute	NULL
)	NULL
and	NULL
detection	NULL
of	NULL
B-cells	NULL
by	NULL
immunofluorescence	NULL
of	NULL
surface	NULL
immunoglob-ulins	NULL
.	NULL

None	NULL
of	NULL
these	NULL
patients	NULL
had	NULL
ever	NULL
received	NULL
chemotherapy	NULL
prior	NULL
to	NULL
the	NULL
time	NULL
of	NULL
the	NULL
study	NULL
.	NULL

All	NULL
experiments	NULL
were	NULL
performed	NULL
at	NULL
the	NULL
time	NULL
of	NULL
the	NULL
first	NULL
examination	NULL
.	NULL

The	NULL
clinical	NULL
features	NULL
of	NULL
the	NULL
patients	NULL
are	NULL
presented	NULL
in	NULL
Table	NULL
1	NULL
.	NULL

Isolation	NULL
of	NULL
Cells	NULL
.	NULL

Leukocytes	NULL
were	NULL
isolated	NULL
within	NULL
2	NULL
hr	NULL
after	NULL
blood	NULL
sampling	NULL
by	NULL
centrifugation	NULL
on	NULL
Ficoll-Hypaque	NULL
(	NULL
6	NULL
)	NULL
.	NULL

After	NULL
2	NULL
washes	NULL
using	NULL
HBSS	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
resuspended	NULL
in	NULL
minimum	NULL
essential	NULL
medium	NULL
(	NULL
Gibco	NULL
Ref	NULL
.	NULL

138	NULL
)	NULL
supplemented	NULL
with	NULL
2	NULL
mm	NULL
glutamine	NULL
(	NULL
Gibco	NULL
Ref	NULL
.	NULL

503	NULL
)	NULL
,	NULL
1	NULL
mm	NULL
sodium	NULL
pyruvate	NULL
(	NULL
Gibco	NULL
Ref	NULL
.	NULL

136	NULL
)	NULL
,	NULL
penicillin	NULL
(	NULL
100	NULL
units/ml	NULL
)	NULL
,	NULL
and	NULL
streptomycin	NULL
(	NULL
100	NULL
ug/ml	NULL
)	NULL
(	NULL
Gibco	NULL
Ref	NULL
.	NULL

507	NULL
)	NULL
and	NULL
1	NULL
%	NULL
(	NULL
v/v	NULL
)	NULL
of	NULL
nonessential	NULL
amino	NULL
acid	NULL
2601	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1980	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

F.	NULL
Homo	NULL
et	NULL
al	NULL
.	NULL

solution	NULL
(	NULL
Gibco	NULL
Ref	NULL
.	NULL

114	NULL
)	NULL
(	NULL
Medium	NULL
A	NULL
)	NULL
and	NULL
adjusted	NULL
to	NULL
a	NULL
concentration	NULL
of	NULL
10	NULL
``	NULL
cells/ml	NULL
.	NULL

The	NULL
cell	NULL
viability	NULL
,	NULL
estimated	NULL
by	NULL
the	NULL
trypan	NULL
blue	NULL
exclusion	NULL
procedure	NULL
(	NULL
37	NULL
)	NULL
,	NULL
was	NULL
always	NULL
above	NULL
95	NULL
%	NULL
at	NULL
the	NULL
end	NULL
of	NULL
the	NULL
cell	NULL
isolation	NULL
procedure	NULL
.	NULL

In	NULL
one	NULL
patient	NULL
(	NULL
S.	NULL
S.	NULL
,	NULL
Patient	NULL
10	NULL
)	NULL
,	NULL
the	NULL
experiment	NULL
was	NULL
performed	NULL
on	NULL
a	NULL
bone	NULL
marrow	NULL
sample	NULL
;	NULL
the	NULL
marrow	NULL
was	NULL
successively	NULL
aspirated	NULL
through	NULL
18-	NULL
,	NULL
22-	NULL
,	NULL
and	NULL
25-gauge	NULL
needles	NULL
to	NULL
obtain	NULL
a	NULL
single-cell	NULL
suspension	NULL
which	NULL
was	NULL
diluted	NULL
in	NULL
HBSS	NULL
and	NULL
then	NULL
centrifuged	NULL
on	NULL
Ficoll-Hypaque	NULL
.	NULL

Isolation	NULL
of	NULL
Cell	NULL
Subpopulations	NULL
.	NULL

The	NULL
separation	NULL
of	NULL
cell	NULL
subpopulations	NULL
by	NULL
centrifugation	NULL
on	NULL
a	NULL
discontinuous	NULL
BSA	NULL
gradient	NULL
was	NULL
performed	NULL
according	NULL
to	NULL
the	NULL
method	NULL
described	NULL
by	NULL
Komuro	NULL
and	NULL
Boyse	NULL
(	NULL
27	NULL
)	NULL
.	NULL

Leukocytes	NULL
(	NULL
2	NULL
to	NULL
4	NULL
x	NULL
10°	NULL
cells	NULL
)	NULL
prepared	NULL
as	NULL
described	NULL
above	NULL
were	NULL
resuspended	NULL
in	NULL
1	NULL
ml	NULL
of	NULL
35	NULL
%	NULL
BSA	NULL
solution	NULL
and	NULL
deposited	NULL
at	NULL
the	NULL
bottom	NULL
of	NULL
1-	NULL
x	NULL
10-cm	NULL
tubes	NULL
.	NULL

One	NULL
ml	NULL
of	NULL
the	NULL
following	NULL
BSA	NULL
solutions	NULL
were	NULL
then	NULL
layered	NULL
successively	NULL
on	NULL
this	NULL
suspension	NULL
:	NULL
29	NULL
%	NULL
,	NULL
26	NULL
%	NULL
,	NULL
23	NULL
%	NULL
,	NULL
and	NULL
10	NULL
%	NULL
.	NULL

After	NULL
30	NULL
min	NULL
centrifugation	NULL
at	NULL
13,000	NULL
x	NULL
g	NULL
(	NULL
4°	NULL
)	NULL
,	NULL
the	NULL
cells	NULL
located	NULL
at	NULL
the	NULL
4	NULL
interfaces	NULL
were	NULL
collected	NULL
and	NULL
washed	NULL
twice	NULL
with	NULL
5	NULL
ml	NULL
HBSS	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
then	NULL
resuspended	NULL
in	NULL
Medium	NULL
A	NULL
,	NULL
counted	NULL
,	NULL
and	NULL
assayed	NULL
for	NULL
°H-nucleoside	NULL
incorporation	NULL
,	NULL
cell	NULL
viability	NULL
,	NULL
pulse	NULL
cytophotometric	NULL
analysis	NULL
,	NULL
and	NULL
May-Griinwald-Giemsa	NULL
staining	NULL
.	NULL

A-cells	NULL
are	NULL
those	NULL
located	NULL
at	NULL
the	NULL
top	NULL
of	NULL
the	NULL
gradient	NULL
between	NULL
the	NULL
23	NULL
and	NULL
10	NULL
%	NULL
BSA	NULL
layers	NULL
,	NULL
B-cells	NULL
are	NULL
located	NULL
between	NULL
26	NULL
and	NULL
23	NULL
%	NULL
BSA	NULL
layers	NULL
,	NULL
C-cells	NULL
are	NULL
located	NULL
between	NULL
29	NULL
and	NULL
26	NULL
%	NULL
BSA	NULL
layers	NULL
,	NULL
and	NULL
D-cells	NULL
are	NULL
located	NULL
between	NULL
the	NULL
35	NULL
and	NULL
29	NULL
%	NULL
BSA	NULL
layers	NULL
.	NULL

In	NULL
each	NULL
experiment	NULL
,	NULL
the	NULL
4	NULL
samples	NULL
A	NULL
,	NULL
B	NULL
,	NULL
C	NULL
,	NULL
and	NULL
D	NULL
were	NULL
adjusted	NULL
to	NULL
the	NULL
same	NULL
concentration	NULL
,	NULL
1	NULL
to	NULL
3	NULL
X	NULL
10°	NULL
cells/	NULL
ml	NULL
.	NULL

As	NULL
previously	NULL
demonstrated	NULL
,	NULL
this	NULL
procedure	NULL
of	NULL
gradient	NULL
separation	NULL
does	NULL
not	NULL
significantly	NULL
alter	NULL
the	NULL
metabolic	NULL
properties	NULL
of	NULL
the	NULL
cells	NULL
(	NULL
13	NULL
,	NULL
22	NULL
)	NULL
.	NULL

Binding	NULL
Assays	NULL
.	NULL

[	NULL
°H	NULL
]	NULL
JDexamethasone	NULL
was	NULL
used	NULL
as	NULL
tracer	NULL
because	NULL
,	NULL
unlike	NULL
endogenous	NULL
cortisol	NULL
,	NULL
it	NULL
has	NULL
low	NULL
affinity	NULL
for	NULL
the	NULL
plasma	NULL
cortisol-binding	NULL
globulin	NULL
.	NULL

The	NULL
methodology	NULL
of	NULL
[	NULL
°H	NULL
}	NULL
dexamethasone	NULL
binding	NULL
studies	NULL
has	NULL
been	NULL
previously	NULL
described	NULL
(	NULL
13	NULL
,	NULL
15	NULL
)	NULL
.	NULL

In	NULL
each	NULL
experiment	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
incubated	NULL
either	NULL
with	NULL
alone	NULL
(	NULL
24	NULL
to	NULL
25	NULL
Ci/mmol	NULL
,	NULL
The	NULL
Radi-ochemical	NULL
Centre	NULL
,	NULL
Amersham	NULL
,	NULL
U.K.	NULL
)	NULL
or	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
an	NULL
excess	NULL
of	NULL
unlabeled	NULL
dexamethasone	NULL
.	NULL

The	NULL
residual	NULL
binding	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
nonradioactive	NULL
steroid	NULL
was	NULL
assumed	NULL
to	NULL
represent	NULL
nonspecific	NULL
binding	NULL
and	NULL
the	NULL
difference	NULL
between	NULL
the	NULL
total	NULL
binding	NULL
of	NULL
[	NULL
°HJdexamethasone	NULL
,	NULL
and	NULL
this	NULL
nonspecific	NULL
binding	NULL
was	NULL
taken	NULL
as	NULL
specific	NULL
binding	NULL
of	NULL
the	NULL
steroid	NULL
hormone	NULL
.	NULL

Steroid	NULL
Effect	NULL
on	NULL
Nucleic	NULL
Acid	NULL
Precursor	NULL
Incorporation	NULL
.	NULL

In	NULL
order	NULL
to	NULL
determine	NULL
the	NULL
steroid	NULL
sensitivity	NULL
of	NULL
the	NULL
cells	NULL
in	NULL
vitro	NULL
,	NULL
we	NULL
measured	NULL
the	NULL
incorporation	NULL
of	NULL
tritiated	NULL
nucleosides	NULL
in	NULL
the	NULL
absence	NULL
(	NULL
control	NULL
)	NULL
or	NULL
presence	NULL
of	NULL
nonradioactive	NULL
dexamethasone	NULL
.	NULL

Previous	NULL
experiments	NULL
performed	NULL
using	NULL
normal	NULL
human	NULL
lymphocytes	NULL
or	NULL
leukemic	NULL
cells	NULL
showed	NULL
that	NULL
short-term	NULL
incubation	NULL
(	NULL
3	NULL
to	NULL
5	NULL
hr	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
steroid	NULL
does	NULL
not	NULL
lead	NULL
to	NULL
any	NULL
marked	NULL
decrease	NULL
in	NULL
precursor	NULL
incorporation	NULL
(	NULL
24	NULL
,	NULL
25	NULL
)	NULL
.	NULL

There-fore	NULL
,	NULL
the	NULL
cell	NULL
suspensions	NULL
were	NULL
preincubated	NULL
for	NULL
22	NULL
hr	NULL
at	NULL
37°	NULL
in	NULL
an	NULL
atmosphere	NULL
of	NULL
5	NULL
%	NULL
CO	NULL
;	NULL
in	NULL
air	NULL
,	NULL
in	NULL
the	NULL
absence	NULL
or	NULL
presence	NULL
of	NULL
107°	NULL
m	NULL
dexamethasone	NULL
,	NULL
and	NULL
then	NULL
received	NULL
1	NULL
of	NULL
either	NULL
[	NULL
}	NULL
HJuridine	NULL
(	NULL
25	NULL
Ci/mmol	NULL
!	NULL
)	NULL

or	NULL
[	NULL
°HJthymidine	NULL
(	NULL
27	NULL
Ci/mmol	NULL
;	NULL
CEA	NULL
France	NULL
)	NULL
for	NULL
a	NULL
2-hr	NULL
pulse	NULL
labeling	NULL
.	NULL

The	NULL
reaction	NULL
was	NULL
terminated	NULL
by	NULL
addition	NULL
of	NULL
ice-cold	NULL
5	NULL
%	NULL
trichloroacetic	NULL
acid	NULL
.	NULL

The	NULL
precipitates	NULL
were	NULL
filtered	NULL
on	NULL
Whatman	NULL
GF/A	NULL
filters	NULL
and	NULL
washed	NULL
3	NULL
times	NULL
with	NULL
10	NULL
ml	NULL
of	NULL
ice-cold	NULL
5	NULL
%	NULL
trichloroacetic	NULL
acid	NULL
.	NULL

The	NULL
radioactivity	NULL
collected	NULL
on	NULL
the	NULL
filters	NULL
was	NULL
counted	NULL
by	NULL
liquid	NULL
scintillation	NULL
spec-trometry	NULL
.	NULL

DNA	NULL
Measurements	NULL
by	NULL
Flow	NULL
System	NULL
Fluorometry	NULL
.	NULL

Aliquots	NULL
of	NULL
the	NULL
cell	NULL
suspension	NULL
isolated	NULL
from	NULL
peripheral	NULL
blood	NULL
by	NULL
cen-	NULL
Table	NULL
1	NULL
Main	NULL
clinical	NULL
,	NULL
hematological	NULL
,	NULL
and	NULL
immunological	NULL
data	NULL
shown	NULL
by	NULL
patients	NULL
at	NULL
time	NULL
of	NULL
examination	NULL
Blood	NULL
Organ	NULL
involvement	NULL
WBC	NULL
Bone	NULL
mar-Patient	NULL
no	NULL
.	NULL

Age	NULL
(	NULL
x	NULL
10°/cu	NULL
-	NULL
Blasts	NULL
row	NULL
blasts	NULL
LN*/SE/	NULL
Type	NULL
of	NULL
leu-and	NULL
initials	NULL
Sex	NULL
(	NULL
yr	NULL
)	NULL
mm	NULL
)	NULL
(	NULL
%	NULL
)	NULL
(	NULL
%	NULL
)	NULL
LE	NULL
Other	NULL
kemia	NULL
1	NULL
.	NULL

F.T	NULL
.	NULL

M	NULL
15	NULL
48.9	NULL
64	NULL
84	NULL
+	NULL
M	NULL
T	NULL
2	NULL
.	NULL

Eh	NULL
.	NULL

W.	NULL
F	NULL
13	NULL
102	NULL
75	NULL
90	NULL
+++	NULL
y	NULL
3	NULL
.	NULL

M.	NULL
C.	NULL
M	NULL
27	NULL
12.1	NULL
88	NULL
95	NULL
+	NULL
4	NULL
.	NULL

Lb	NULL
.	NULL

V.	NULL
F	NULL
4	NULL
40.3	NULL
B9	NULL
100	NULL
++	NULL
N	NULL
§	NULL
.	NULL

T.	NULL
M.	NULL
M	NULL
33	NULL
230	NULL
91	NULL
95	NULL
+	NULL
T	NULL
6	NULL
.	NULL

C.F	NULL
.	NULL

M	NULL
11	NULL
44.5	NULL
94	NULL
78	NULL
++	NULL
T	NULL
7	NULL
.	NULL

B.F.	NULL
M	NULL
3	NULL
18.5	NULL
0	NULL
42	NULL
-	NULL
T	NULL
8	NULL
.	NULL

C.	NULL
G.	NULL
F	NULL
6	NULL
33.8	NULL
89	NULL
85	NULL
-	NULL
N	NULL
9	NULL
.	NULL

C.	NULL
R.	NULL
F	NULL
ass	NULL
5.4	NULL
33	NULL
so	NULL
++	NULL
b	NULL
10	NULL
.	NULL

S.S.	NULL
M	NULL
12	NULL
5.7	NULL
24	NULL
100	NULL
+++	NULL
CNS	NULL
B	NULL
11	NULL
.	NULL

0	NULL
.	NULL

D.	NULL
M	NULL
6	NULL
48.6	NULL
97	NULL
97	NULL
+++	NULL
N	NULL
12	NULL
.	NULL

S.F	NULL
.	NULL

M	NULL
3	NULL
14.3	NULL
78	NULL
100	NULL
-	NULL
N	NULL
13	NULL
.	NULL

T.	NULL
M.	NULL
M	NULL
5	NULL
16.5	NULL
71	NULL
100	NULL
+	NULL
N	NULL
14	NULL
.	NULL

C.	NULL
N	NULL
F	NULL
11	NULL
19.2	NULL
74	NULL
100	NULL
-	NULL
N	NULL
15	NULL
.	NULL

C.	NULL
M.	NULL
M	NULL
50	NULL
40	NULL
99	NULL
100	NULL
+	NULL
N	NULL
16	NULL
.	NULL

S.1	NULL
.	NULL

F	NULL
2	NULL
5.3	NULL
0	NULL
94	NULL
-	NULL
b	NULL
17	NULL
.	NULL

R.	NULL
R.	NULL
M	NULL
57	NULL
334	NULL
Bo	NULL
70	NULL
+	NULL
CML	NULL
(	NULL
BC	NULL
)	NULL
18	NULL
.	NULL

R.	NULL
A.	NULL
M	NULL
4	NULL
14.7	NULL
56	NULL
94	NULL
++	NULL
N	NULL
19.	NULL
c.	NULL
v.	NULL
F	NULL
57	NULL
1.9	NULL
51	NULL
40	NULL
-	NULL
b	NULL
20	NULL
.	NULL

G.	NULL
G.	NULL
M	NULL
29	NULL
68	NULL
86	NULL
91.5	NULL
++	NULL
T	NULL
21	NULL
.	NULL

LL	NULL
.	NULL

F	NULL
3	NULL
27.3	NULL
91	NULL
100	NULL
-	NULL
N	NULL
22	NULL
.	NULL

S.	NULL
S.	NULL
F	NULL
15	NULL
2.7	NULL
14	NULL
9	NULL
-	NULL
N	NULL
23	NULL
.	NULL

M.	NULL
U.	NULL
M	NULL
76	NULL
12	NULL
71	NULL
60	NULL
-	NULL
N	NULL
24	NULL
.	NULL

P.	NULL
M.	NULL
F	NULL
3	NULL
18.6	NULL
43	NULL
100	NULL
+	NULL
N	NULL
25	NULL
.	NULL

B.	NULL
J.	NULL
M.	NULL
M	NULL
20	NULL
86	NULL
86	NULL
64	NULL
+++	NULL
T	NULL
26	NULL
.	NULL

R.	NULL
Y.	NULL
F	NULL
51	NULL
150	NULL
70	NULL
82	NULL
-	NULL
CNS	NULL
CML	NULL
(	NULL
BC	NULL
)	NULL
®	NULL
LN	NULL
,	NULL
lymph	NULL
nodes	NULL
;	NULL
SE	NULL
,	NULL
spleen	NULL
enlargement	NULL
;	NULL
LE	NULL
,	NULL
liver	NULL
enlargement	NULL
;	NULL
M	NULL
,	NULL
mediastinum	NULL
;	NULL
T	NULL
,	NULL
T-cell-derived	NULL
;	NULL
N	NULL
,	NULL
null	NULL
cell	NULL
;	NULL
CNS	NULL
,	NULL
central	NULL
nervous	NULL
system	NULL
;	NULL
B	NULL
,	NULL
bone	NULL
marrow-derived	NULL
;	NULL
CML	NULL
(	NULL
BC	NULL
)	NULL
,	NULL
chronic	NULL
myelocytic	NULL
leukemia	NULL
in	NULL
``	NULL
lymphoid	NULL
``	NULL
blast	NULL
crisis	NULL
.	NULL

The	NULL
immunological	NULL
characterization	NULL
of	NULL
the	NULL
patient	NULL
was	NULL
not	NULL
performed	NULL
.	NULL

2602	NULL
CANCER	NULL
RESEARCH	NULL
VOL	NULL
.	NULL

40	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1980	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

trifugation	NULL
on	NULL
Ficoll-Hypaque	NULL
(	NULL
0.5	NULL
ml	NULL
,	NULL
10°	NULL
cells/ml	NULL
)	NULL
were	NULL
fixed	NULL
in	NULL
methanol	NULL
(	NULL
final	NULL
concentration	NULL
,	NULL
50	NULL
%	NULL
)	NULL
,	NULL
washed	NULL
in	NULL
phosphate-buffered	NULL
saline	NULL
(	NULL
pH	NULL
7.4	NULL
)	NULL
,	NULL
and	NULL
incubated	NULL
for	NULL
20	NULL
min	NULL
at	NULL
37°	NULL
in	NULL
phosphate-buffered	NULL
saline	NULL
containing	NULL
RNase	NULL
(	NULL
50	NULL
ug/ml	NULL
;	NULL
3000	NULL
units/mg	NULL
;	NULL
Worthington	NULL
)	NULL
.	NULL

At	NULL
the	NULL
end	NULL
of	NULL
the	NULL
incubation	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
washed	NULL
and	NULL
resuspended	NULL
in	NULL
1	NULL
ml	NULL
propidium	NULL
iodide	NULL
solution	NULL
(	NULL
50	NULL
mg	NULL
propidium	NULL
iodide	NULL
and	NULL
1	NULL
g	NULL
sodium	NULL
citrate	NULL
per	NULL
liter	NULL
)	NULL
.	NULL

Pulse	NULL
cytophotometric	NULL
measurements	NULL
were	NULL
performed	NULL
within	NULL
1	NULL
hr	NULL
of	NULL
staining	NULL
using	NULL
a	NULL
Cytofluorograf	NULL
(	NULL
4802	NULL
A	NULL
;	NULL
Biophysic	NULL
Sys-tems	NULL
,	NULL
Inc.	NULL
,	NULL
Mahopac	NULL
,	NULL
N	NULL
.	NULL

Y	NULL
.	NULL
)	NULL

.	NULL

DNA	NULL
histograms	NULL
were	NULL
evaluated	NULL
by	NULL
planimetry	NULL
(	NULL
20	NULL
)	NULL
.	NULL

Statistical	NULL
Analysis	NULL
.	NULL

Correlations	NULL
were	NULL
estimated	NULL
by	NULL
determination	NULL
of	NULL
the	NULL
regression	NULL
lines	NULL
using	NULL
the	NULL
least	NULL
square	NULL
method	NULL
.	NULL

RESULTS	NULL
Determination	NULL
of	NULL
Glucocorticoid	NULL
Receptors	NULL
in	NULL
Acute	NULL
Leukemia	NULL
.	NULL

Chart	NULL
1	NULL
(	NULL
right	NULL
)	NULL
shows	NULL
the	NULL
values	NULL
of	NULL
glucocorticoid-binding	NULL
sites	NULL
,	NULL
determined	NULL
by	NULL
Scatchard	NULL
plot	NULL
analysis	NULL
(	NULL
40	NULL
)	NULL
,	NULL
in	NULL
23	NULL
patients	NULL
.	NULL

The	NULL
concentration	NULL
of	NULL
glucocorticoid	NULL
receptors	NULL
varied	NULL
widely	NULL
from	NULL
one	NULL
patient	NULL
to	NULL
another	NULL
,	NULL
ranging	NULL
from	NULL
2,600	NULL
to	NULL
19,200	NULL
sites	NULL
per	NULL
cell	NULL
.	NULL
'	NULL

The	NULL
mean	NULL
receptor	NULL
value	NULL
was	NULL
about	NULL
9000	NULL
sites	NULL
[	NULL
9140	NULL
+	NULL
4390	NULL
(	NULL
S.D	NULL
.	NULL
)	NULL

;	NULL
n	NULL
=	NULL
23	NULL
]	NULL
per	NULL
cell	NULL
.	NULL

Dissociation	NULL
constants	NULL
,	NULL
determined	NULL
from	NULL
the	NULL
slope	NULL
of	NULL
the	NULL
Scatchard	NULL
plots	NULL
,	NULL
were	NULL
in	NULL
the	NULL
range	NULL
of	NULL
1.2	NULL
to	NULL
6.7	NULL
x	NULL
10~°	NULL
m	NULL
(	NULL
3.9	NULL
+	NULL
1.6	NULL
x	NULL
10~°	NULL
m	NULL
;	NULL
n	NULL
=	NULL
23	NULL
)	NULL
and	NULL
appeared	NULL
similar	NULL
to	NULL
those	NULL
determined	NULL
for	NULL
dexamethasone-re-ceptor	NULL
interaction	NULL
in	NULL
normal	NULL
human	NULL
lymphocytes	NULL
(	NULL
Chart	NULL
1	NULL
,	NULL
/eft	NULL
)	NULL
.	NULL

Attempts	NULL
have	NULL
been	NULL
made	NULL
to	NULL
correlate	NULL
the	NULL
level	NULL
of	NULL
steroid	NULL
receptors	NULL
with	NULL
several	NULL
parameters	NULL
including	NULL
immunological	NULL
markers	NULL
,	NULL
WBC	NULL
,	NULL
and	NULL
patients	NULL
'	NULL
sex	NULL
or	NULL
age	NULL
.	NULL

The	NULL
results	NULL
presented	NULL
in	NULL
Table	NULL
2	NULL
reveal	NULL
that	NULL
the	NULL
number	NULL
of	NULL
glucocorticoid	NULL
receptors	NULL
tends	NULL
to	NULL
be	NULL
higher	NULL
in	NULL
males	NULL
than	NULL
in	NULL
females	NULL
.	NULL

Konior-Yarbro	NULL
et	NULL
al	NULL
.	NULL

(	NULL
28	NULL
)	NULL
also	NULL
mentioned	NULL
some	NULL
variation	NULL
in	NULL
the	NULL
level	NULL
of	NULL
glucocorticoid	NULL
receptors	NULL
with	NULL
sex	NULL
and	NULL
age	NULL
,	NULL
but	NULL
their	NULL
results	NULL
were	NULL
not	NULL
statistically	NULL
significant	NULL
.	NULL

This	NULL
possible	NULL
sex	NULL
difference	NULL
in	NULL
receptor	NULL
level	NULL
should	NULL
therefore	NULL
be	NULL
confirmed	NULL
in	NULL
more	NULL
extensive	NULL
studies	NULL
.	NULL

Within	NULL
our	NULL
group	NULL
of	NULL
patients	NULL
,	NULL
no	NULL
significant	NULL
difference	NULL
in	NULL
receptor	NULL
content	NULL
between	NULL
T-cell	NULL
and	NULL
``	NULL
null	NULL
``	NULL
cell	NULL
acute	NULL
leukemia	NULL
was	NULL
10	NULL
20000	NULL
®	NULL
-	NULL
U	NULL
aE	NULL
bnd	NULL
@	NULL
s	NULL
x	NULL
&	NULL
x	NULL
R	NULL
«	NULL
a	NULL
[	NULL
3	NULL
*	NULL
*	NULL
=	NULL
]	NULL
f=3	NULL
e	NULL
w	NULL
to	NULL
€	NULL
s-	NULL
m	NULL
8	NULL
410000	NULL
R	NULL
3	NULL
%	NULL
Se	NULL
=	NULL
mex	NULL
00g	NULL
2	NULL
=	NULL
ma	NULL
H	NULL
F	NULL
a	NULL
I	NULL
§	NULL
&	NULL
O	NULL
2	NULL
o	NULL
6	NULL
«	NULL
a	NULL
U	NULL
co	NULL
e	NULL
Chart	NULL
1	NULL
.	NULL

Specific	NULL
binding	NULL
of	NULL
[	NULL
°H	NULL
}	NULL
dexamethasone	NULL
(	NULL
right	NULL
)	NULL
and	NULL
the	NULL
apparent	NULL
dissociation	NULL
constant	NULL
of	NULL
steroid-receptor	NULL
interaction	NULL
(	NULL
K	NULL
...	NULL
,	NULL
37°	NULL
,	NULL
left	NULL
)	NULL
were	NULL
determined	NULL
in	NULL
leukocytes	NULL
isolated	NULL
from	NULL
the	NULL
blood	NULL
of	NULL
23	NULL
patients	NULL
.	NULL

In	NULL
each	NULL
case	NULL
,	NULL
these	NULL
values	NULL
were	NULL
calculated	NULL
by	NULL
Scatchard	NULL
plot	NULL
anaysis	NULL
.	NULL

-	NULL
--	NULL
-	NULL
,	NULL
means	NULL
of	NULL
individual	NULL
determinations	NULL
.	NULL

JULY	NULL
1980	NULL
In	NULL
Vitro	NULL
Response	NULL
to	NULL
Glucocorticoids	NULL
in	NULL
Acute	NULL
Leukemia	NULL
Table	NULL
2	NULL
Number	NULL
of	NULL
glucocorticoid	NULL
receptors	NULL
in	NULL
leukocytes	NULL
isolated	NULL
from	NULL
the	NULL
blood	NULL
of	NULL
patients	NULL
with	NULL
ALL	NULL
or	NULL
chronic	NULL
myelocytic	NULL
leukemia	NULL
in	NULL
``	NULL
lymphoid	NULL
``	NULL
blast	NULL
crisis	NULL
in	NULL
relation	NULL
to	NULL
sex	NULL
and	NULL
age	NULL
Glucocorticoid	NULL
recep-	NULL
_	NULL
WBC	NULL
(	NULL
x	NULL
10°/	NULL
tors	NULL
cu	NULL
mm	NULL
)	NULL
ALL	NULL
``	NULL
Null	NULL
``	NULL
cell	NULL
Female	NULL
5.958	NULL
+	NULL
2.336	NULL
``	NULL
(	NULL
6	NULL
)	NULL
°	NULL
<	NULL
10	NULL
yr	NULL
5,657	NULL
+	NULL
2,906	NULL
(	NULL
4	NULL
)	NULL
22.2	NULL
£	NULL
15.8	NULL
>	NULL
10	NULL
yr	NULL
6,560	NULL
(	NULL
2	NULL
)	NULL
60.6	NULL
Male	NULL
10,128	NULL
+	NULL
3,332	NULL
(	NULL
6	NULL
)	NULL
<	NULL
10	NULL
yr	NULL
10,087	NULL
+	NULL
2,606	NULL
(	NULL
4	NULL
)	NULL
23.5	NULL
+	NULL
16.7	NULL
>	NULL
10	NULL
yr	NULL
10,210	NULL
(	NULL
2	NULL
)	NULL
26	NULL
T-cell	NULL
(	NULL
male	NULL
)	NULL
10,365	NULL
+	NULL
4,990	NULL
(	NULL
6	NULL
)	NULL
<	NULL
10	NULL
yr	NULL
5,820°	NULL
(	NULL
1	NULL
)	NULL
18.5	NULL
>	NULL
10	NULL
yr	NULL
11,274	NULL
+	NULL
4,993	NULL
(	NULL
5	NULL
)	NULL
95.5	NULL
+	NULL
76.9	NULL
Chronic	NULL
myelocytic	NULL
leukemia	NULL
in	NULL
``	NULL
lymphoid	NULL
``	NULL
blast	NULL
crisis	NULL
Female	NULL
7,830	NULL
(	NULL
1	NULL
)	NULL
334	NULL
Male	NULL
12,240	NULL
(	NULL
1	NULL
)	NULL
150	NULL
``	NULL
Mean	NULL
+	NULL
S.D	NULL
.	NULL

Numbers	NULL
in	NULL
parentheses	NULL
,	NULL
number	NULL
of	NULL
patients	NULL
.	NULL

©	NULL
This	NULL
patient	NULL
(	NULL
Patient	NULL
7	NULL
)	NULL
does	NULL
not	NULL
exhibit	NULL
circulating	NULL
lymphoblasts	NULL
.	NULL

apparent	NULL
,	NULL
in	NULL
contrast	NULL
with	NULL
previously	NULL
reported	NULL
results	NULL
(	NULL
28	NULL
)	NULL
.	NULL

These	NULL
discrepancies	NULL
might	NULL
be	NULL
related	NULL
to	NULL
differences	NULL
in	NULL
methodology	NULL
as	NULL
discussed	NULL
elsewhere	NULL
(	NULL
14	NULL
)	NULL
.	NULL

Absence	NULL
of	NULL
Correlation	NULL
between	NULL
the	NULL
Effects	NULL
of	NULL
Glucocorticoid	NULL
in	NULL
Vitro	NULL
and	NULL
the	NULL
Levels	NULL
of	NULL
Glucocorticoid	NULL
Receptors	NULL
.	NULL

Attempts	NULL
have	NULL
been	NULL
made	NULL
to	NULL
establish	NULL
a	NULL
correlation	NULL
between	NULL
the	NULL
level	NULL
of	NULL
glucocorticoid	NULL
receptors	NULL
and	NULL
the	NULL
inhibitory	NULL
effects	NULL
of	NULL
steroids	NULL
on	NULL
uridine	NULL
and	NULL
thymidine	NULL
incorporation	NULL
in	NULL
vitro	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Chart	NULL
2	NULL
,	NULL
no	NULL
correlation	NULL
could	NULL
be	NULL
found	NULL
between	NULL
the	NULL
number	NULL
of	NULL
steroid-binding	NULL
sites	NULL
and	NULL
the	NULL
percentage	NULL
of	NULL
steroid-induced	NULL
inhibition	NULL
of	NULL
both	NULL
uridine	NULL
and	NULL
thymidine	NULL
incorporations	NULL
.	NULL

Moreover	NULL
,	NULL
in	NULL
some	NULL
patients	NULL
,	NULL
we	NULL
have	NULL
even	NULL
noted	NULL
a	NULL
stimulation	NULL
of	NULL
nucleoside	NULL
incorporation	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
dexamethasone	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
the	NULL
sex	NULL
difference	NULL
observed	NULL
in	NULL
terms	NULL
of	NULL
glucocorticoid	NULL
receptors	NULL
is	NULL
not	NULL
associated	NULL
with	NULL
any	NULL
sex	NULL
difference	NULL
in	NULL
steroid	NULL
sensitivity	NULL
.	NULL

Dexamethasone-induced	NULL
inhibition	NULL
of	NULL
uridine	NULL
and	NULL
thymidine	NULL
incorporation	NULL
is	NULL
plotted	NULL
as	NULL
a	NULL
function	NULL
of	NULL
the	NULL
spontaneous	NULL
levels	NULL
of	NULL
nucleoside	NULL
incorporation	NULL
Chart	NULL
3	NULL
.	NULL

A	NULL
significant	NULL
correlation	NULL
exists	NULL
between	NULL
these	NULL
parameters	NULL
(	NULL
r	NULL
=	NULL
0.49	NULL
,	NULL
p	NULL
<	NULL
0.01	NULL
,	NULL
n	NULL
=	NULL
25	NULL
and	NULL
r	NULL
=	NULL
0.51	NULL
,	NULL
p	NULL
<	NULL
0.01	NULL
,	NULL
n	NULL
=	NULL
25	NULL
for	NULL
uridine	NULL
and	NULL
thymidine	NULL
,	NULL
respectively	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
the	NULL
effects	NULL
of	NULL
the	NULL
steroid	NULL
in	NULL
vitro	NULL
could	NULL
be	NULL
linked	NULL
to	NULL
the	NULL
proliferative	NULL
and	NULL
metabolic	NULL
state	NULL
of	NULL
the	NULL
cells	NULL
.	NULL

The	NULL
effect	NULL
of	NULL
dexamethasone	NULL
on	NULL
cell	NULL
viability	NULL
,	NULL
which	NULL
represents	NULL
the	NULL
end	NULL
point	NULL
of	NULL
the	NULL
steroid	NULL
action	NULL
,	NULL
was	NULL
also	NULL
determined	NULL
over	NULL
a	NULL
22-hr	NULL
incubation	NULL
period	NULL
in	NULL
vitro	NULL
,	NULL
in	NULL
relation	NULL
to	NULL
receptor	NULL
levels	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Chart	NULL
4	NULL
,	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
steroid	NULL
,	NULL
the	NULL
cell	NULL
viability	NULL
remained	NULL
>	NULL
75	NULL
%	NULL
in	NULL
15	NULL
of	NULL
23	NULL
patients	NULL
and	NULL
showed	NULL
only	NULL
an	NULL
appreciable	NULL
decrease	NULL
in	NULL
8	NULL
of	NULL
23	NULL
patients	NULL
.	NULL

Dexamethasone	NULL
(	NULL
10~	NULL
``	NULL
m	NULL
)	NULL
produced	NULL
a	NULL
supplementary	NULL
diminution	NULL
of	NULL
cell	NULL
viability	NULL
in	NULL
only	NULL
7	NULL
of	NULL
23	NULL
patients	NULL
.	NULL

This	NULL
effect	NULL
was	NULL
more	NULL
frequent	NULL
in	NULL
those	NULL
patients	NULL
who	NULL
showed	NULL
an	NULL
already	NULL
high	NULL
incidence	NULL
of	NULL
spontaneous	NULL
cell	NULL
death	NULL
(	NULL
5	NULL
of	NULL
8	NULL
)	NULL
.	NULL

Under	NULL
similar	NULL
conditions	NULL
,	NULL
the	NULL
viability	NULL
of	NULL
normal	NULL
human	NULL
peripheral	NULL
Iymphocytes	NULL
remained	NULL
virtually	NULL
unaffected	NULL
by	NULL
steroid	NULL
(	NULL
25	NULL
)	NULL
.	NULL

Again	NULL
,	NULL
no	NULL
correlation	NULL
could	NULL
be	NULL
found	NULL
between	NULL
the	NULL
lytic	NULL
effect	NULL
of	NULL
steroid	NULL
in	NULL
vitro	NULL
and	NULL
the	NULL
number	NULL
of	NULL
glucocorticoid	NULL
receptors	NULL
.	NULL

Relationship	NULL
between	NULL
the	NULL
Absence	NULL
or	NULL
Presence	NULL
of	NULL
Cells	NULL
in	NULL
the	NULL
S	NULL
Phase	NULL
of	NULL
the	NULL
Cell	NULL
Cycle	NULL
and	NULL
the	NULL
Inhibitory	NULL
Effect	NULL
of	NULL
2603	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1980	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

W1	NULL
&	NULL
3	NULL
6	NULL
2	NULL
&	NULL
.	NULL

1	NULL
u	NULL
t	NULL
u	NULL
t	NULL
az	NULL
100	NULL
,	NULL
u	NULL
r	NULL
v	NULL
T	NULL
3	NULL
€	NULL
f	NULL
s	NULL
=	NULL
>	NULL
pas	NULL
oo	NULL
H-	NULL
0	NULL
e	NULL
f-	NULL
fa	NULL
i	NULL
a	NULL
a	NULL
5	NULL
e	NULL
&	NULL
t	NULL
0	NULL
5	NULL
o	NULL
e	NULL
*	NULL
.	NULL

[	NULL
-	NULL
o	NULL
&	NULL
soho	NULL
,	NULL
``	NULL
o	NULL
R	NULL
»	NULL
|S	NULL
59-	NULL
e	NULL
e	NULL
h	NULL
&	NULL
az	NULL
©	NULL
,	NULL
©	NULL
``	NULL
~	NULL
U	NULL
E	NULL
u	NULL
o	NULL
R	NULL
3	NULL
°	NULL
ba	NULL
®	NULL
an	NULL
.	NULL

==	NULL
=	NULL
0	NULL
#	NULL
f-	NULL
o	NULL
3	NULL
o	NULL
o	NULL
-	NULL
>	NULL
®	NULL
0	NULL
,	NULL
W	NULL
*	NULL
€	NULL
,	NULL
R	NULL
4	NULL
re	NULL
0	NULL
Lad	NULL
0	NULL
+	NULL
+	NULL
U	NULL
=	NULL
e	NULL
*	NULL
a=	NULL
B	NULL
=	NULL
=	NULL
=	NULL
at	NULL
E4	NULL
~	NULL
``	NULL
150	NULL
i	NULL
o	NULL
i	NULL
ao	NULL
45	NULL
usp	NULL
il	NULL
i	NULL
a	NULL
10000	NULL
20000	NULL
10000	NULL
20000	NULL
SITES	NULL
PER	NULL
CELL	NULL
SITES	NULL
PER	NULL
CELL	NULL
Chart	NULL
2	NULL
.	NULL

Percentages	NULL
of	NULL
steroid-induced	NULL
inhibition	NULL
of	NULL
[	NULL
*HJuridine	NULL
incorporation	NULL
(	NULL
eft	NULL
)	NULL
and	NULL
[	NULL
°HJthymidine	NULL
incorporation	NULL
(	NULL
right	NULL
)	NULL
are	NULL
plotted	NULL
as	NULL
a	NULL
function	NULL
of	NULL
the	NULL
number	NULL
of	NULL
binding	NULL
sites	NULL
per	NULL
cell	NULL
in	NULL
22	NULL
patients	NULL
.	NULL

O	NULL
,	NULL
female	NULL
patients	NULL
;	NULL
@	NULL
,	NULL
male	NULL
patients	NULL
.	NULL

JL	NULL
/a	NULL
am	NULL
T	NULL
U	NULL
T	NULL
:	NULL
\	NULL
:	NULL
100F-	NULL
7	NULL
E.	NULL
1	NULL
o	NULL
7	NULL
we	NULL
o	NULL
q	NULL
F	NULL
3	NULL
a	NULL
@	NULL
o	NULL
o	NULL
[	NULL
3	NULL
[	NULL
7	NULL
§	NULL
|	NULL
>	NULL
.	NULL

B	NULL
to	NULL
>	NULL
a	NULL
o	NULL
®	NULL
%	NULL
o	NULL
®	NULL
o	NULL
=	NULL
o	NULL
o	NULL
a	NULL
50F-	NULL
0	NULL
.	NULL

p	NULL
1	NULL
&	NULL
»	NULL
SOP	NULL
o	NULL
h	NULL
as	NULL
%	NULL
®	NULL
-	NULL
0	NULL
e	NULL
®	NULL
0	NULL
ae	NULL
mas	NULL
e	NULL
0	NULL
e	NULL
mad	NULL
E	NULL
0	NULL
®	NULL
®	NULL
o	NULL
|	NULL
,	NULL
:	NULL
a	NULL
|	NULL
}	NULL
.	NULL

E	NULL
o	NULL
.°	NULL
E-	NULL
e	NULL
°	NULL
a	NULL
»	NULL
e*	NULL
,	NULL
R	NULL
A	NULL
E	NULL
.	NULL

,	NULL
i	NULL
/L	NULL
i	NULL
0	NULL
+	NULL
t	NULL
+	NULL
a	NULL
°	NULL
-	NULL
.	NULL

1	NULL
&	NULL
=	NULL
&	NULL
°	NULL
t	NULL
=	NULL
a	NULL
a	NULL
as	NULL
an	NULL
#	NULL
J	NULL
=	NULL
50	NULL
a_	NULL
1	NULL
1	NULL
i	NULL
**	NULL
cso	NULL
1	NULL
i	NULL
5000	NULL
``	NULL
2000	NULL
5/2000	NULL
(	NULL
31	NULL
)	NULL
unining	NULL
inconposation	NULL
BM	NULL
)	NULL
TEYMIDINE	NULL
inNCoRPeRATION	NULL
(	NULL
cpm	NULL
/	NULL
106	NULL
cells	NULL
)	NULL
{	NULL
cpm	NULL
/	NULL
108	NULL
cells	NULL
)	NULL
Chart	NULL
3	NULL
.	NULL

Percentages	NULL
of	NULL
steroid-induced	NULL
inhibition	NULL
of	NULL
[	NULL
°HJuridine	NULL
incorporation	NULL
(	NULL
left	NULL
)	NULL
and	NULL
[	NULL
°HJ	NULL
}	NULL
thymidine	NULL
incorporation	NULL
(	NULL
right	NULL
)	NULL
are	NULL
plotted	NULL
as	NULL
a	NULL
function	NULL
of	NULL
the	NULL
spontaneous	NULL
levels	NULL
of	NULL
nucleosides	NULL
incorporation	NULL
(	NULL
/.e	NULL
.	NULL

,	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
steroid	NULL
)	NULL
over	NULL
a	NULL
24-hr	NULL
period	NULL
in	NULL
25	NULL
patients	NULL
.	NULL

O	NULL
,	NULL
female	NULL
patients	NULL
;	NULL
®	NULL
,	NULL
male	NULL
patients	NULL
.	NULL

Dexamethasone	NULL
on	NULL
[	NULL
°HJThymidine	NULL
Incorporation	NULL
.	NULL

As	NULL
mentioned	NULL
above	NULL
,	NULL
there	NULL
is	NULL
a	NULL
significant	NULL
correlation	NULL
between	NULL
the	NULL
level	NULL
of	NULL
[	NULL
°HIthymidine	NULL
incorporation	NULL
and	NULL
the	NULL
extent	NULL
of	NULL
the	NULL
inhibitory	NULL
effect	NULL
of	NULL
dexamethasone	NULL
.	NULL

In	NULL
order	NULL
to	NULL
focus	NULL
on	NULL
this	NULL
relationship	NULL
,	NULL
we	NULL
have	NULL
divided	NULL
our	NULL
patients	NULL
into	NULL
2	NULL
groups	NULL
according	NULL
to	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
cells	NULL
in	NULL
S	NULL
phase	NULL
,	NULL
determined	NULL
by	NULL
pulse	NULL
cytophotometry	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Table	NULL
3	NULL
,	NULL
the	NULL
inhibitory	NULL
effect	NULL
of	NULL
dexamethasone	NULL
on	NULL
thymidine	NULL
incorporation	NULL
is	NULL
markedly	NULL
higher	NULL
in	NULL
the	NULL
group	NULL
possessing	NULL
an	NULL
appreciable	NULL
proportion	NULL
of	NULL
cells	NULL
in	NULL
S	NULL
phase	NULL
than	NULL
in	NULL
the	NULL
group	NULL
with	NULL
no	NULL
detectable	NULL
circulating	NULL
cells	NULL
in	NULL
S	NULL
phase	NULL
.	NULL

No	NULL
difference	NULL
could	NULL
be	NULL
seen	NULL
between	NULL
male	NULL
and	NULL
female	NULL
patients	NULL
in	NULL
terms	NULL
of	NULL
the	NULL
proportion	NULL
of	NULL
cells	NULL
in	NULL
the	NULL
S	NULL
phase	NULL
and	NULL
steroid	NULL
inhibition	NULL
,	NULL
although	NULL
the	NULL
number	NULL
of	NULL
binding	NULL
sites	NULL
appears	NULL
to	NULL
be	NULL
higher	NULL
in	NULL
male	NULL
than	NULL
in	NULL
female	NULL
patients	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
the	NULL
mean	NULL
value	NULL
of	NULL
WBC	NULL
is	NULL
consistently	NULL
but	NULL
not	NULL
significantly	NULL
lower	NULL
in	NULL
patients	NULL
with	NULL
no	NULL
cells	NULL
in	NULL
S	NULL
phase	NULL
than	NULL
in	NULL
patients	NULL
with	NULL
an	NULL
appreciable	NULL
proportion	NULL
of	NULL
these	NULL
cells	NULL
.	NULL

Relationship	NULL
between	NULL
the	NULL
Proportion	NULL
of	NULL
Cells	NULL
in	NULL
the	NULL
S	NULL
Phase	NULL
and	NULL
Spontaneous	NULL
or	NULL
Dexamethasone-induced	NULL
Cell	NULL
Lysis	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Table	NULL
4	NULL
,	NULL
there	NULL
is	NULL
a	NULL
parallelism	NULL
between	NULL
the	NULL
2604	NULL
pattern	NULL
of	NULL
cell	NULL
viability	NULL
and	NULL
the	NULL
proportion	NULL
of	NULL
cells	NULL
in	NULL
the	NULL
S	NULL
phase	NULL
.	NULL

This	NULL
percentage	NULL
tends	NULL
to	NULL
be	NULL
higher	NULL
in	NULL
the	NULL
group	NULL
of	NULL
patients	NULL
whose	NULL
cells	NULL
exhibit	NULL
spontaneous	NULL
cell	NULL
death	NULL
than	NULL
in	NULL
the	NULL
group	NULL
of	NULL
patients	NULL
with	NULL
no	NULL
cell	NULL
death	NULL
(	NULL
5.4	NULL
+	NULL
3.5	NULL
versus	NULL
3.8	NULL
+	NULL
4.8	NULL
%	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
within	NULL
the	NULL
group	NULL
showing	NULL
steroid-induced	NULL
aggravation	NULL
of	NULL
cell	NULL
death	NULL
,	NULL
the	NULL
porportion	NULL
of	NULL
cells	NULL
in	NULL
S	NULL
phase	NULL
appears	NULL
still	NULL
higher	NULL
(	NULL
7	NULL
+	NULL
3.7	NULL
%	NULL
)	NULL
.	NULL

The	NULL
incidence	NULL
of	NULL
patients	NULL
showing	NULL
an	NULL
appreciable	NULL
percentage	NULL
of	NULL
cells	NULL
in	NULL
S	NULL
phase	NULL
is	NULL
6	NULL
of	NULL
13	NULL
in	NULL
the	NULL
group	NULL
with	NULL
a	NULL
spontaneous	NULL
viability	NULL
of	NULL
>	NULL
75	NULL
%	NULL
,	NULL
7	NULL
of	NULL
8	NULL
in	NULL
the	NULL
group	NULL
with	NULL
a	NULL
spontaneous	NULL
viability	NULL
of	NULL
<	NULL
75	NULL
%	NULL
,	NULL
and	NULL
7	NULL
of	NULL
7	NULL
in	NULL
the	NULL
group	NULL
showing	NULL
steroid-induced	NULL
cell	NULL
lysis	NULL
.	NULL

As	NULL
also	NULL
shown	NULL
in	NULL
Table	NULL
4	NULL
,	NULL
the	NULL
WBC	NULL
tends	NULL
to	NULL
be	NULL
lower	NULL
in	NULL
the	NULL
group	NULL
of	NULL
patients	NULL
with	NULL
a	NULL
cell	NULL
viability	NULL
of	NULL
>	NULL
75	NULL
%	NULL
than	NULL
in	NULL
the	NULL
2	NULL
other	NULL
groups	NULL
.	NULL

Absence	NULL
of	NULL
Relationship	NULL
between	NULL
the	NULL
Proportion	NULL
of	NULL
Cells	NULL
in	NULL
the	NULL
S	NULL
Phase	NULL
of	NULL
the	NULL
Cell	NULL
Cycle	NULL
(	NULL
Measured	NULL
at	NULL
the	NULL
Time	NULL
of	NULL
Blood	NULL
Sampling	NULL
)	NULL
and	NULL
the	NULL
Level	NULL
of	NULL
[	NULL
°HJThymidine	NULL
incorporation	NULL
after	NULL
24	NULL
Hr	NULL
Incubation	NULL
in	NULL
Vitro	NULL
.	NULL

Analysis	NULL
of	NULL
the	NULL
results	NULL
presented	NULL
above	NULL
revealed	NULL
that	NULL
some	NULL
patients	NULL
with	NULL
a	NULL
high	NULL
percentage	NULL
of	NULL
ceils	NULL
in	NULL
the	NULL
S	NULL
phase	NULL
,	NULL
when	NULL
measured	NULL
at	NULL
the	NULL
time	NULL
of	NULL
blood	NULL
sampling	NULL
(	NULL
which	NULL
represents	NULL
the	NULL
time	NULL
zero	NULL
of	NULL
the	NULL
experi-ment	NULL
)	NULL
,	NULL
do	NULL
not	NULL
necessarily	NULL
exhibit	NULL
a	NULL
high	NULL
level	NULL
of	NULL
thymidine	NULL
incorporation	NULL
as	NULL
measured	NULL
by	NULL
a	NULL
2-hr	NULL
pulse	NULL
labeling	NULL
after	NULL
22	NULL
hr	NULL
incubation	NULL
in	NULL
vitro	NULL
.	NULL

Thus	NULL
,	NULL
each	NULL
of	NULL
the	NULL
2	NULL
groups	NULL
of	NULL
patients	NULL
previously	NULL
classified	NULL
according	NULL
to	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
cells	NULL
in	NULL
S	NULL
phase	NULL
could	NULL
be	NULL
further	NULL
subdivided	NULL
into	NULL
2	NULL
groups	NULL
.	NULL

Among	NULL
the	NULL
patients	NULL
with	NULL
a	NULL
high	NULL
percentage	NULL
of	NULL
cells	NULL
in	NULL
S	NULL
phase	NULL
at	NULL
the	NULL
time	NULL
of	NULL
blood	NULL
sampling	NULL
,	NULL
Group	NULL
III	NULL
contains	NULL
the	NULL
patients	NULL
whose	NULL
cells	NULL
showed	NULL
a	NULL
high	NULL
level	NULL
of	NULL
[	NULL
°HJthymidine	NULL
incorporation	NULL
after	NULL
24	NULL
hr	NULL
incubation	NULL
,	NULL
whereas	NULL
Group	NULL
IV	NULL
contains	NULL
the	NULL
patients	NULL
with	NULL
a	NULL
low	NULL
[	NULL
°HIthymidine	NULL
incorporation	NULL
.	NULL

Patients	NULL
with	NULL
no	NULL
appreciable	NULL
proportion	NULL
of	NULL
cells	NULL
in	NULL
S	NULL
phase	NULL
and	NULL
low	NULL
levels	NULL
of	NULL
thymidine	NULL
incorporation	NULL
are	NULL
separated	NULL
into	NULL
2	NULL
groups	NULL
,	NULL
I	NULL
and	NULL
II	NULL
,	NULL
according	NULL
to	NULL
the	NULL
pattern	NULL
of	NULL
cell	NULL
viability	NULL
.	NULL

in	NULL
Group	NULL
II	NULL
,	NULL
the	NULL
percentage	NULL
of	NULL
viable	NULL
cells	NULL
remained	NULL
over	NULL
75	NULL
%	NULL
in	NULL
the	NULL
absence	NULL
as	NULL
well	NULL
as	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
10~®	NULL
m	NULL
dexamethasone	NULL
;	NULL
whereas	NULL
in	NULL
Group	NULL
I	NULL
,	NULL
the	NULL
percentage	NULL
of	NULL
viable	NULL
cells	NULL
is	NULL
lower	NULL
than	NULL
75	NULL
%	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Chart	NULL
5	NULL
,	NULL
both	NULL
nucleoside	NULL
incorporations	NULL
and	NULL
the	NULL
inhibitory	NULL
effects	NULL
of	NULL
dexamethasone	NULL
increase	NULL
in	NULL
parallel	NULL
from	NULL
Group	NULL
I	NULL
to	NULL
Group	NULL
III	NULL
and	NULL
then	NULL
decrease	NULL
in	NULL
Group	NULL
IV	NULL
,	NULL
which	NULL
still	NULL
confirms	NULL
the	NULL
correlation	NULL
between	NULL
the	NULL
levels	NULL
of	NULL
nucleoside	NULL
incorporation	NULL
and	NULL
the	NULL
extent	NULL
of	NULL
steroid	NULL
action	NULL
.	NULL

The	NULL
pattern	NULL
of	NULL
cell	NULL
viability	NULL
appears	NULL
highly	NULL
variable	NULL
in	NULL
Groups	NULL
III	NULL
and	NULL
IV	NULL
,	NULL
whether	NULL
or	NULL
not	NULL
it	NULL
is	NULL
affected	NULL
by	NULL
the	NULL
steroid	NULL
in	NULL
vitro	NULL
.	NULL

Group	NULL
III	NULL
contains	NULL
U	NULL
T	NULL
'°0F	NULL
o	NULL
_	NULL
ase	NULL
o	NULL
e	NULL
O	NULL
o	NULL
-	NULL
se	NULL
=	NULL
61	NULL
q	NULL
|	NULL
|	NULL
3	NULL
+P	NULL
o1	NULL
6p	NULL
|	NULL
«	NULL
g	NULL
_	NULL
a	NULL
H	NULL
1	NULL
F	NULL
I	NULL
S	NULL
``	NULL
J	NULL
.	NULL

4	NULL
4	NULL
|	NULL
3	NULL
a	NULL
|	NULL
us	NULL
é	NULL
o	NULL
e	NULL
1	NULL
F	NULL
10000	NULL
20000	NULL
SITES	NULL
PER	NULL
CELL	NULL
Chart	NULL
4	NULL
.	NULL

Percentage	NULL
of	NULL
viable	NULL
cells	NULL
after	NULL
22-hr	NULL
incubations	NULL
in	NULL
vitro	NULL
in	NULL
lymphoid	NULL
cells	NULL
isolated	NULL
from	NULL
the	NULL
blood	NULL
of	NULL
23	NULL
patients	NULL
.	NULL

®	NULL
,	NULL
spontaneous	NULL
viability	NULL
(	NULL
i.e	NULL
.	NULL

,	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
steroid	NULL
)	NULL
;	NULL
O	NULL
,	NULL
percentage	NULL
of	NULL
viable	NULL
cells	NULL
after	NULL
22-hr	NULL
incubation	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
10~°	NULL
m	NULL
dexamethasone	NULL
,	NULL
-	NULL
-	NULL
-	NULL
-	NULL
,	NULL
the	NULL
75	NULL
%	NULL
limit	NULL
of	NULL
cell	NULL
viability	NULL
.	NULL

CANCER	NULL
RESEARCH	NULL
VOL	NULL
.	NULL

40	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1980	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

In	NULL
Vitro	NULL
Response	NULL
to	NULL
Glucocorticoids	NULL
in	NULL
Acute	NULL
Leukemia	NULL
Table	NULL
3	NULL
Number	NULL
of	NULL
glucocorticoid	NULL
receptors	NULL
and	NULL
inhibitory	NULL
effects	NULL
of	NULL
dexamethasone	NULL
on	NULL
[	NULL
°HJthymidine	NULL
incorporation	NULL
in	NULL
relation	NULL
to	NULL
the	NULL
proportion	NULL
of	NULL
cells	NULL
in	NULL
the	NULL
S	NULL
phase	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
The	NULL
level	NULL
of	NULL
thymidine	NULL
incorporation	NULL
,	NULL
measured	NULL
in	NULL
a	NULL
2-hr	NULL
pulse	NULL
,	NULL
after	NULL
22	NULL
hr	NULL
incubation	NULL
in	NULL
vitro	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
steroid	NULL
was	NULL
taken	NULL
as	NULL
100	NULL
%	NULL
,	NULL
and	NULL
the	NULL
inhibitory	NULL
effect	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
10~°	NULL
m	NULL
dexamethasone	NULL
is	NULL
expressed	NULL
as	NULL
a	NULL
percentage	NULL
thereof	NULL
.	NULL

The	NULL
percentage	NULL
of	NULL
cells	NULL
in	NULL
the	NULL
S	NULL
phase	NULL
was	NULL
determined	NULL
by	NULL
pulse	NULL
cytophotometry	NULL
analysis	NULL
.	NULL

Inhibition	NULL
of	NULL
thymidine	NULL
in-	NULL
_	NULL
Glucocorticoid	NULL
Age	NULL
of	NULL
No	NULL
.	NULL

of	NULL
_	NULL
Celis	NULL
in	NULL
S	NULL
$	NULL
_	NULL
corporation	NULL
-	NULL
receptors	NULL
(	NULL
sites/	NULL
-	NULL
WBC	NULL
(	NULL
x10°/	NULL
patients	NULL
patients	NULL
-	NULL
phase	NULL
(	NULL
%	NULL
)	NULL
(	NULL
%	NULL
)	NULL
cell	NULL
)	NULL
cu	NULL
mm	NULL
)	NULL
Type	NULL
of	NULL
leukemia	NULL
(	NULL
yr	NULL
)	NULL
Female	NULL
4	NULL
6.6	NULL
%	NULL
1.9	NULL
``	NULL
54.8	NULL
+	NULL
19.7	NULL
6,050	NULL
£1,970	NULL
70.5	NULL
+	NULL
68.8	NULL
3	NULL
N.	NULL
”	NULL
1	NULL
3	NULL
<	NULL
15	NULL
CML	NULL
(	NULL
BC	NULL
)	NULL
1	NULL
>	NULL
50	NULL
Male	NULL
9	NULL
7.3	NULL
+	NULL
3.7	NULL
49.8	NULL
£	NULL
29.4	NULL
11,280	NULL
£	NULL
4,145	NULL
87.4	NULL
£	NULL
116	NULL
5	NULL
N	NULL
,	NULL
2	NULL
T	NULL
,	NULL
1	NULL
B	NULL
,	NULL
1	NULL
4	NULL
<	NULL
15	NULL
CML	NULL
(	NULL
BC	NULL
)	NULL
1	NULL
=	NULL
20	NULL
4	NULL
>	NULL
30	NULL
Female	NULL
5	NULL
0	NULL
22.1	NULL
#	NULL
23.9	NULL
5,680	NULL
+	NULL
2,540	NULL
17.8	NULL
%	NULL
14.3	NULL
3N	NULL
,	NULL
.2°	NULL
4	NULL
<	NULL
15	NULL
1	NULL
>	NULL
80	NULL
Male	NULL
4	NULL
0	NULL
26	NULL
#	NULL
142	NULL
11,070	NULL
+	NULL
6,360	NULL
34.8	NULL
+	NULL
26.50	NULL
2N,1T,1°	NULL
2	NULL
<	NULL
15	NULL
2	NULL
>	NULL
20	NULL
``	NULL
Mean	NULL
+	NULL
S.D	NULL
.	NULL

b	NULL
N	NULL
,	NULL
null	NULL
cell-derived	NULL
;	NULL
CML	NULL
(	NULL
BC	NULL
)	NULL
,	NULL
chronic	NULL
myelocytic	NULL
leukemia	NULL
in	NULL
``	NULL
lymphoid	NULL
``	NULL
blast	NULL
crisis	NULL
;	NULL
T	NULL
,	NULL
T-cell-derived	NULL
;	NULL
B	NULL
,	NULL
B-cell-	NULL
derived	NULL
.	NULL

©	NULL
Immunological	NULL
characterization	NULL
was	NULL
not	NULL
performed	NULL
.	NULL

Table	NULL
4	NULL
The	NULL
patterns	NULL
of	NULL
cell	NULL
viability	NULL
after	NULL
22	NULL
hr	NULL
incubation	NULL
in	NULL
the	NULL
absence	NULL
(	NULL
spontaneous	NULL
)	NULL
or	NULL
presence	NULL
of	NULL
10~°	NULL
m	NULL
dexamethasone	NULL
in	NULL
relation	NULL
to	NULL
the	NULL
percentage	NULL
of	NULL
cells	NULL
in	NULL
the	NULL
S	NULL
phase	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
No	NULL
.	NULL

of	NULL
patients	NULL
with	NULL
cells	NULL
Cells	NULL
in	NULL
S	NULL
in	NULL
S	NULL
WBC	NULL
(	NULL
x10°/cu	NULL
Age	NULL
of	NULL
pa-Cell	NULL
viability	NULL
(	NULL
22	NULL
hr	NULL
incubation	NULL
)	NULL
phase	NULL
(	NULL
%	NULL
)	NULL
phase	NULL
mm	NULL
)	NULL
Type	NULL
of	NULL
leukemia	NULL
tients	NULL
(	NULL
yr	NULL
)	NULL
Spontaneous	NULL
viability	NULL
>	NULL
75	NULL
%	NULL
sszaas	NULL
``	NULL
t	NULL
-	NULL
e/is	NULL
'	NULL
as	NULL
+	NULL
sr	NULL
?	NULL

7N'5t.18B	NULL
,	NULL
.2	NULL
``	NULL
10	NULL
<	NULL
i5	NULL
(	NULL
n	NULL
=	NULL
15	NULL
)	NULL
3	NULL
=	NULL
30	NULL
2	NULL
>	NULL
50	NULL
Spontaneous	NULL
viability	NULL
<	NULL
75	NULL
%	NULL
5.4	NULL
#	NULL
3.5	NULL
7/	NULL
8	NULL
85.5	NULL
x	NULL
111.3	NULL
5	NULL
N	NULL
,	NULL
1	NULL
T	NULL
,	NULL
2	NULL
CML	NULL
(	NULL
BC	NULL
)	NULL
5	NULL
<	NULL
15	NULL
(	NULL
n	NULL
=	NULL
8	NULL
)	NULL
1	NULL
=	NULL
20	NULL
2	NULL
>	NULL
50	NULL
Dexamethasone-induced	NULL
cell	NULL
7	NULL
#	NULL
3.7	NULL
7/	NULL
7	NULL
95.9	NULL
£	NULL
131.4	NULL
§	NULL
N	NULL
,	NULL
1	NULL
T	NULL
,	NULL
1	NULL
CML	NULL
(	NULL
BC	NULL
)	NULL
4	NULL
<	NULL
15	NULL
lysis	NULL
(	NULL
n	NULL
=	NULL
7	NULL
)	NULL
1	NULL
=	NULL
30	NULL
2	NULL
>	NULL
50	NULL
``	NULL
Mean	NULL
+	NULL
S.D	NULL
.	NULL

Determinations	NULL
were	NULL
made	NULL
in	NULL
13	NULL
of	NULL
15	NULL
patients	NULL
.	NULL

°	NULL
N	NULL
,	NULL
null-cell-derived	NULL
;	NULL
T	NULL
,	NULL
T-cell-derived	NULL
;	NULL
B	NULL
,	NULL
B-cell-derived	NULL
;	NULL
CML	NULL
(	NULL
BC	NULL
)	NULL
,	NULL
chronic	NULL
myelocytic	NULL
leukemia	NULL
with	NULL
``	NULL
lymphoid	NULL
blast	NULL
crisis	NULL
.	NULL

Immunological	NULL
characterization	NULL
was	NULL
not	NULL
performed	NULL
.	NULL

patients	NULL
showing	NULL
clinical	NULL
characteristics	NULL
generally	NULL
considered	NULL
as	NULL
indicative	NULL
of	NULL
a	NULL
poor	NULL
prognosis	NULL
:	NULL
2	NULL
patients	NULL
over	NULL
15	NULL
years	NULL
of	NULL
age	NULL
with	NULL
``	NULL
null	NULL
``	NULL
cell	NULL
leukemia	NULL
;	NULL
2	NULL
adult	NULL
patients	NULL
with	NULL
T-cell	NULL
leukemia	NULL
;	NULL
and	NULL
2	NULL
patients	NULL
ages	NULL
around	NULL
50	NULL
years	NULL
with	NULL
chronic	NULL
myelocytic	NULL
leukemia	NULL
in	NULL
``	NULL
lymphoid	NULL
``	NULL
blast	NULL
crisis	NULL
.	NULL

This	NULL
group	NULL
is	NULL
also	NULL
characterized	NULL
in	NULL
general	NULL
by	NULL
a	NULL
high	NULL
WBC	NULL
and	NULL
a	NULL
male	NULL
predominancy	NULL
.	NULL

Cell	NULL
Heterogeneity	NULL
.	NULL

Tables	NULL
5	NULL
and	NULL
6	NULL
show	NULL
several	NULL
parameters	NULL
(	NULL
distribution	NULL
,	NULL
viability	NULL
,	NULL
proportion	NULL
of	NULL
cells	NULL
in	NULL
S	NULL
phase	NULL
,	NULL
levels	NULL
of	NULL
[	NULL
®HIthymidine	NULL
incorporation	NULL
,	NULL
and	NULL
inhibitory	NULL
effects	NULL
of	NULL
steroid	NULL
in	NULL
vitro	NULL
)	NULL
determined	NULL
in	NULL
4	NULL
patients	NULL
after	NULL
isolation	NULL
of	NULL
subpopulations	NULL
by	NULL
centrifugation	NULL
on	NULL
a	NULL
discontinuous	NULL
BSA	NULL
gradient	NULL
.	NULL

From	NULL
the	NULL
results	NULL
obtained	NULL
after	NULL
gradient	NULL
separation	NULL
,	NULL
several	NULL
points	NULL
may	NULL
be	NULL
underlined	NULL
:	NULL
(	NULL
a	NULL
)	NULL
the	NULL
cell	NULL
distribution	NULL
along	NULL
the	NULL
gradient	NULL
appears	NULL
markedly	NULL
different	NULL
from	NULL
one	NULL
patient	NULL
to	NULL
another	NULL
,	NULL
even	NULL
in	NULL
the	NULL
2	NULL
patients	NULL
with	NULL
similar	NULL
clinical	NULL
and	NULL
immunological	NULL
features	NULL
(	NULL
Table	NULL
5	NULL
,	NULL
Patients	NULL
B.	NULL
J.	NULL
M.	NULL
and	NULL
G.	NULL
G.	NULL
)	NULL
.	NULL

in	NULL
general	NULL
,	NULL
the	NULL
vast	NULL
majority	NULL
of	NULL
cells	NULL
are	NULL
located	NULL
in	NULL
the	NULL
lightest	NULL
fractions	NULL
of	NULL
the	NULL
gradient	NULL
(	NULL
A	NULL
and	NULL
B	NULL
)	NULL
;	NULL
(	NULL
b	NULL
)	NULL
in	NULL
a	NULL
given	NULL
patient	NULL
,	NULL
the	NULL
subpopulations	NULL
appear	NULL
markedly	NULL
different	NULL
in	NULL
terms	NULL
of	NULL
spontaneous	NULL
or	NULL
dexamethasone-induced	NULL
cell	NULL
lysis	NULL
(	NULL
Table	NULL
5	NULL
)	NULL
;	NULL
(	NULL
c	NULL
)	NULL
similarly	NULL
,	NULL
the	NULL
level	NULL
of	NULL
[	NULL
°HIthymidine	NULL
incorporation	NULL
varies	NULL
markedly	NULL
from	NULL
one	NULL
subpopulation	NULL
to	NULL
another	NULL
both	NULL
between	NULL
patients	NULL
and	NULL
JULY	NULL
1980	NULL
within	NULL
a	NULL
given	NULL
patient	NULL
(	NULL
Table	NULL
6	NULL
)	NULL
.	NULL

The	NULL
upper	NULL
layer	NULL
of	NULL
the	NULL
gradient	NULL
(	NULL
Subfraction	NULL
A	NULL
)	NULL
appears	NULL
,	NULL
however	NULL
,	NULL
enriched	NULL
in	NULL
proliferative	NULL
blast	NULL
cell	NULL
as	NULL
determined	NULL
by	NULL
thymidine	NULL
incorporation	NULL
,	NULL
pulse	NULL
cytophotometry	NULL
analysis	NULL
,	NULL
and	NULL
also	NULL
smear	NULL
examination	NULL
in	NULL
good	NULL
agreement	NULL
with	NULL
previously	NULL
published	NULL
results	NULL
(	NULL
10	NULL
,	NULL
38	NULL
,	NULL
43	NULL
)	NULL
;	NULL
(	NULL
d	NULL
)	NULL
the	NULL
percentage	NULL
of	NULL
steroid-induced	NULL
inhibition	NULL
of	NULL
thymidine	NULL
incorporation	NULL
is	NULL
generally	NULL
maximal	NULL
in	NULL
the	NULL
light	NULL
fraction	NULL
(	NULL
Subfraction	NULL
A	NULL
)	NULL
,	NULL
but	NULL
this	NULL
high	NULL
inhibitory	NULL
effect	NULL
does	NULL
not	NULL
appear	NULL
to	NULL
be	NULL
necessarily	NULL
associated	NULL
with	NULL
steroid-induced	NULL
cell	NULL
lysis	NULL
.	NULL

Thymidine	NULL
incorporation	NULL
is	NULL
sometimes	NULL
slightly	NULL
stimulated	NULL
by	NULL
dexamethasone	NULL
in	NULL
the	NULL
dense	NULL
fractions	NULL
(	NULL
Subfractions	NULL
C	NULL
and	NULL
D	NULL
)	NULL
.	NULL

In	NULL
some	NULL
cases	NULL
,	NULL
granulocytes	NULL
or	NULL
monocytes	NULL
could	NULL
be	NULL
observed	NULL
in	NULL
these	NULL
fractions	NULL
by	NULL
smear	NULL
examinations	NULL
.	NULL

Response	NULL
to	NULL
Short-Term	NULL
Glucocorticoid	NULL
Therapy	NULL
.	NULL

Eleven	NULL
patients	NULL
were	NULL
treated	NULL
with	NULL
prednisone	NULL
(	NULL
40	NULL
mg/sq	NULL
m	NULL
)	NULL
for	NULL
2	NULL
to	NULL
4	NULL
days	NULL
before	NULL
starting	NULL
combined	NULL
chemotherapy	NULL
.	NULL

Among	NULL
these	NULL
patients	NULL
,	NULL
only	NULL
6	NULL
responded	NULL
to	NULL
steroids	NULL
by	NULL
a	NULL
marked	NULL
decrease	NULL
both	NULL
in	NULL
WBC	NULL
and	NULL
in	NULL
the	NULL
level	NULL
of	NULL
circulating	NULL
blast	NULL
cells	NULL
.	NULL

The	NULL
clinical	NULL
features	NULL
and	NULL
the	NULL
results	NULL
of	NULL
in	NULL
vitro	NULL
determinations	NULL
in	NULL
responding	NULL
and	NULL
nonresponding	NULL
patients	NULL
are	NULL
compared	NULL
in	NULL
Table	NULL
7	NULL
.	NULL

No	NULL
significant	NULL
differences	NULL
could	NULL
be	NULL
found	NULL
between	NULL
these	NULL
2	NULL
groups	NULL
in	NULL
terms	NULL
of	NULL
glucocorticoid	NULL
receptors	NULL
or	NULL
in	NULL
terms	NULL
of	NULL
inhibition	NULL
of	NULL
nucleoside	NULL
incorporation	NULL
by	NULL
dexamethasone	NULL
and	NULL
2605	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1980	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

F.	NULL
Homo	NULL
et	NULL
al	NULL
.	NULL

5000	NULL
INCORPORATION	NULL
Of	NULL
(	NULL
BH	NULL
)	NULL
-THYMIOINE	NULL
(	NULL
c	NULL
)	NULL
Or	NULL
{	NULL
cpm	NULL
/	NULL
105	NULL
cells	NULL
)	NULL
(	NULL
3M	NULL
)	NULL
-URIOINE	NULL
(	NULL
=	NULL
)	NULL
INCORPORATION	NULL
|	NULL
(	NULL
3NJ-URIDINE	NULL
(	NULL
0	NULL
)	NULL
(	NULL
24	NULL
hr	NULL
)	NULL
50	NULL
INHIBITION	NULL
of	NULL
(	NULL
3M	NULL
)	NULL
-	NULL
THYMIDINE	NULL
(	NULL
@	NULL
)	NULL
OR	NULL
(	NULL
zahr	NULL
)	NULL
(	NULL
%	NULL
)	NULL
ma	NULL
sammy	NULL
S	NULL
Za	NULL
NUMBER	NULL
OF	NULL
PATIENTS	NULL
CELLS	NULL
IN	NULL
THE	NULL
S	NULL
PHASE	NULL
(	NULL
%	NULL
)	NULL
#	NULL
T1*3.6	NULL
Chart	NULL
5	NULL
.	NULL

Results	NULL
of	NULL
in	NULL
vitro	NULL
experiments	NULL
performed	NULL
in	NULL
patients	NULL
in	NULL
Groups	NULL
I	NULL
to	NULL
IV	NULL
.	NULL

Top	NULL
,	NULL
levels	NULL
of	NULL
[	NULL
°HJthymidine	NULL
and	NULL
[	NULL
°HJuridine	NULL
incorporation	NULL
,	NULL
expressed	NULL
as	NULL
cpm/	NULL
10°	NULL
viable	NULL
cells	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
incubated	NULL
for	NULL
22	NULL
hr	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
dexamethasone	NULL
and	NULL
then	NULL
received	NULL
1	NULL
uCi	NULL
of	NULL
either	NULL
thymidine	NULL
or	NULL
uridine	NULL
for	NULL
an	NULL
additional	NULL
2	NULL
hr	NULL
of	NULL
pulse	NULL
labeling	NULL
.	NULL

Bottom	NULL
,	NULL
percentages	NULL
of	NULL
steroid-induced	NULL
inhibition	NULL
of	NULL
[	NULL
HJthymidine	NULL
and	NULL
[	NULL
*HJuridine	NULL
incorporation	NULL
in	NULL
patients	NULL
in	NULL
Groups	NULL
I	NULL
to	NULL
IV	NULL
.	NULL

steroid-induced	NULL
cell	NULL
lysis	NULL
.	NULL

Similarly	NULL
,	NULL
there	NULL
were	NULL
no	NULL
striking	NULL
differences	NULL
in	NULL
clinical	NULL
features	NULL
between	NULL
the	NULL
2	NULL
groups	NULL
.	NULL

DISCUSSION	NULL
The	NULL
proliferative	NULL
activity	NULL
of	NULL
leukemic	NULL
cells	NULL
in	NULL
acute	NULL
leukemia	NULL
has	NULL
been	NULL
under	NULL
investigation	NULL
for	NULL
a	NULL
long	NULL
time	NULL
.	NULL

In	NULL
former	NULL
autora-diographic	NULL
observations	NULL
and	NULL
determinations	NULL
of	NULL
the	NULL
mitotic	NULL
index	NULL
or	NULL
,	NULL
more	NULL
recently	NULL
,	NULL
pulse	NULL
cytophotometry	NULL
analysis	NULL
,	NULL
low	NULL
percentages	NULL
of	NULL
bone	NULL
marrow	NULL
cells	NULL
in	NULL
S	NULL
and	NULL
G	NULL
;	NULL
+	NULL
M	NULL
phases	NULL
have	NULL
been	NULL
found	NULL
in	NULL
untreated	NULL
ALL	NULL
patients	NULL
(	NULL
19	NULL
,	NULL
21	NULL
,	NULL
26	NULL
,	NULL
35	NULL
)	NULL
.	NULL

Except	NULL
for	NULL
some	NULL
patients	NULL
with	NULL
ALL	NULL
,	NULL
there	NULL
exist	NULL
in	NULL
all	NULL
types	NULL
of	NULL
acute	NULL
leukemia	NULL
more	NULL
cells	NULL
in	NULL
the	NULL
S	NULL
phase	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
in	NULL
the	NULL
bone	NULL
marrow	NULL
than	NULL
in	NULL
peripheral	NULL
blood	NULL
(	NULL
19	NULL
,	NULL
35	NULL
)	NULL
.	NULL

Under	NULL
normal	NULL
conditions	NULL
,	NULL
very	NULL
few	NULL
proliferating	NULL
cells	NULL
enter	NULL
the	NULL
circulation	NULL
;	NULL
while	NULL
in	NULL
acute	NULL
leukemia	NULL
,	NULL
bone	NULL
marrow	NULL
blasts	NULL
generally	NULL
escape	NULL
into	NULL
the	NULL
peripheral	NULL
blood	NULL
.	NULL

In	NULL
some	NULL
ALL	NULL
patients	NULL
,	NULL
however	NULL
,	NULL
the	NULL
dominant	NULL
migration	NULL
may	NULL
be	NULL
in	NULL
the	NULL
opposite	NULL
direction	NULL
.	NULL

Small	NULL
diurnal	NULL
variations	NULL
in	NULL
the	NULL
number	NULL
of	NULL
cells	NULL
synthesizing	NULL
DNA	NULL
were	NULL
also	NULL
seen	NULL
in	NULL
the	NULL
bone	NULL
marrow	NULL
of	NULL
some	NULL
patients	NULL
,	NULL
as	NULL
well	NULL
as	NULL
a	NULL
periodicity	NULL
in	NULL
the	NULL
appearance	NULL
of	NULL
labeled	NULL
cells	NULL
in	NULL
the	NULL
peripheral	NULL
blood	NULL
after	NULL
thymidine	NULL
injection	NULL
in	NULL
vivo	NULL
,	NULL
suggesting	NULL
that	NULL
some	NULL
control	NULL
mechanism	NULL
for	NULL
bone	NULL
marrow	NULL
release	NULL
is	NULL
at	NULL
work	NULL
(	NULL
19	NULL
,	NULL
39	NULL
)	NULL
.	NULL

Several	NULL
investigators	NULL
have	NULL
emphasized	NULL
that	NULL
,	NULL
in	NULL
a	NULL
given	NULL
patient	NULL
,	NULL
blasts	NULL
can	NULL
not	NULL
be	NULL
considered	NULL
as	NULL
a	NULL
single	NULL
homogeneous	NULL
population	NULL
and	NULL
that	NULL
a	NULL
classification	NULL
could	NULL
be	NULL
achieved	NULL
on	NULL
the	NULL
Table	NULL
5	NULL
Distribution	NULL
and	NULL
patterns	NULL
of	NULL
viability	NULL
in	NULL
subfractions	NULL
isolated	NULL
by	NULL
centrifugation	NULL
on	NULL
a	NULL
discontinuous	NULL
BSA	NULL
gradient	NULL
Arrows	NULL
denote	NULL
a	NULL
dexamethasone-induced	NULL
decrease	NULL
of	NULL
cell	NULL
viability	NULL
after	NULL
22	NULL
hr	NULL
incubation	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
10~°	NULL
m	NULL
steroid	NULL
.	NULL

Patient	NULL
B.	NULL
J.	NULL
M.	NULL
,	NULL
male	NULL
,	NULL
20	NULL
years	NULL
old	NULL
,	NULL
86,000	NULL
WBC/cu	NULL
mm	NULL
,	NULL
T-cell-derived	NULL
ALL	NULL
;	NULL
Patient	NULL
G.	NULL
G.	NULL
,	NULL
male	NULL
,	NULL
29	NULL
years	NULL
old	NULL
,	NULL
68,000	NULL
WBC	NULL
/cu	NULL
mm	NULL
,	NULL
T-cell-derived	NULL
ALL	NULL
;	NULL
Patient	NULL
S.	NULL
S.	NULL
,	NULL
female	NULL
,	NULL
15	NULL
years	NULL
old	NULL
,	NULL
2,700	NULL
WBC/cu	NULL
mm	NULL
,	NULL
null	NULL
cell	NULL
ALL	NULL
;	NULL
Patient	NULL
R.	NULL
Y.	NULL
,	NULL
female	NULL
,	NULL
51	NULL
years	NULL
old	NULL
,	NULL
150,000	NULL
WBC/cu	NULL
mm	NULL
,	NULL
chronic	NULL
myelocytic	NULL
leukemia	NULL
in	NULL
``	NULL
lymphoid	NULL
``	NULL
blast	NULL
crisis	NULL
.	NULL

B.	NULL
J.	NULL
M.	NULL
G.	NULL
G.	NULL
S.	NULL
S.	NULL
R.	NULL
Y	NULL
.	NULL

Viability	NULL
(	NULL
%	NULL
)	NULL
Via-Cell	NULL
-	NULL
Con-	NULL
_	NULL
10°	NULL
``	NULL
m	NULL
Cell	NULL
_	NULL
bility	NULL
_	NULL
Cell	NULL
Cell	NULL
Subfraction	NULL
(	NULL
%	NULL
)	NULL
_	NULL
trol	NULL
steroid	NULL
(	NULL
%	NULL
)	NULL
(	NULL
%	NULL
)	NULL
(	NULL
%	NULL
)	NULL
Viability	NULL
(	NULL
%	NULL
)	NULL
(	NULL
%	NULL
)	NULL
Viability	NULL
(	NULL
%	NULL
)	NULL
Unseparated	NULL
pop-	NULL
30	NULL
75	NULL
73	NULL
Ind	NULL
44	NULL
30	NULL
ulation	NULL
A	NULL
70.9	NULL
-	NULL
31	NULL
-	NULL
»	NULL
4	NULL
33.9	NULL
70	NULL
67.5	NULL
70	NULL
-	NULL
40	NULL
18	NULL
54	NULL
-	NULL
-	NULL
23	NULL
B	NULL
16.3	NULL
66	NULL
-	NULL
39	NULL
§3.5	NULL
75	NULL
22.8	NULL
78	NULL
-	NULL
60	NULL
47.2	NULL
31	NULL
-	NULL
9	NULL
C	NULL
7.4	NULL
70	NULL
6.4	NULL
-	NULL
80	NULL
4.6	NULL
65	NULL
-	NULL
§40	NULL
23.50	NULL
41	NULL
-	NULL
23	NULL
D	NULL
5.4	NULL
85	NULL
6.2	NULL
95	NULL
5.1	NULL
45	NULL
11.3	NULL
65	NULL
Table	NULL
6	NULL
Levels	NULL
of	NULL
spontaneous	NULL
[	NULL
*HJthymidine	NULL
incorporation	NULL
and	NULL
dexamethasone-induced	NULL
inhibition	NULL
of	NULL
nucleoside	NULL
incorporation	NULL
in	NULL
leukocyte	NULL
subpopulations	NULL
isolated	NULL
by	NULL
centrifugation	NULL
on	NULL
BSA	NULL
gradient	NULL
in	NULL
4	NULL
patients	NULL
with	NULL
acute	NULL
leukemia	NULL
B.	NULL
J.	NULL
M.	NULL
``	NULL
G.	NULL
G.	NULL
S.	NULL
S.	NULL
R.	NULL
Y.	NULL
incor-incorpo-	NULL
pora-	NULL
Incorporation	NULL
tion	NULL
ration	NULL
incorpora-	NULL
(	NULL
cpm/	NULL
(	NULL
cpm/	NULL
(	NULL
cpm/	NULL
tion	NULL
10°	NULL
Inhibi-	NULL
10°	NULL
_	NULL
Inhibition	NULL
10°	NULL
Inhibi-	NULL
(	NULL
cpm/10°	NULL
_	NULL
Inhibi-Subfraction	NULL
cells	NULL
)	NULL
tion	NULL
(	NULL
%	NULL
)	NULL
cells	NULL
)	NULL
(	NULL
%	NULL
)	NULL
cells	NULL
)	NULL
tion	NULL
(	NULL
%	NULL
)	NULL
cells	NULL
)	NULL
tion	NULL
(	NULL
%	NULL
)	NULL
Unseparated	NULL
pop-	NULL
1,120	NULL
-6.5	NULL
146	NULL
10.8	NULL
703	NULL
56.6	NULL
3,051	NULL
40.5	NULL
ulation	NULL
A	NULL
2,252	NULL
25.1	NULL
399	NULL
32.2	NULL
2,154	NULL
73.8	NULL
12,516	NULL
74.5	NULL
B	NULL
1,780	NULL
8.3	NULL
195	NULL
3	NULL
326	NULL
24.7	NULL
6,782	NULL
78	NULL
C	NULL
214	NULL
-2.9	NULL
453	NULL
9.3	NULL
5,117	NULL
34.1	NULL
D	NULL
119	NULL
-14.2	NULL
350	NULL
-5.4	NULL
3,035	NULL
32.1	NULL
``	NULL
For	NULL
patient	NULL
information	NULL
,	NULL
see	NULL
legend	NULL
to	NULL
Table	NULL
5	NULL
.	NULL

2606	NULL
CANCER	NULL
RESEARCH	NULL
VOL	NULL
.	NULL

40	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1980	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

In	NULL
Vitro	NULL
Response	NULL
to	NULL
Glucocorticoids	NULL
in	NULL
Acute	NULL
Leukemia	NULL
Table	NULL
7	NULL
Number	NULL
of	NULL
glucocorticoid	NULL
receptors	NULL
and	NULL
percentages	NULL
of	NULL
inhibition	NULL
of	NULL
thymidine	NULL
incorporation	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
10~°	NULL
m	NULL
dexamethasone	NULL
determined	NULL
in	NULL
11	NULL
patients	NULL
with	NULL
ALL	NULL
before	NULL
the	NULL
start	NULL
of	NULL
corticotherapy	NULL
Patients	NULL
have	NULL
been	NULL
subdivided	NULL
into	NULL
responders	NULL
and	NULL
nonresponders	NULL
on	NULL
the	NULL
basis	NULL
of	NULL
a	NULL
50	NULL
%	NULL
decrease	NULL
in	NULL
the	NULL
number	NULL
of	NULL
circulating	NULL
blast	NULL
cells	NULL
after	NULL
treatment	NULL
.	NULL

Glucocorticoid	NULL
re-	NULL
Sex	NULL
ra-Blasts	NULL
(	NULL
x	NULL
10°/	NULL
ceptor	NULL
tio	NULL
(	NULL
M/	NULL
Type	NULL
of	NULL
cu	NULL
min	NULL
)	NULL
(	NULL
sites/cell	NULL
)	NULL
_	NULL
Inhibition	NULL
(	NULL
%	NULL
)	NULL
F	NULL
)	NULL
Age	NULL
(	NULL
yr	NULL
)	NULL
-	NULL
leukemia	NULL
Positive	NULL
response	NULL
Before	NULL
32.1	NULL
+	NULL
25°	NULL
8,275	NULL
After	NULL
5.5	NULL
#	NULL
4.1	NULL
b	NULL
Female	NULL
5,565	NULL
41.5	NULL
#	NULL
21.8	NULL
3/3	NULL
6	NULL
<	NULL
15	NULL
SN	NULL
,	NULL
``	NULL
1T	NULL
Male	NULL
10,080	NULL
Negative	NULL
response	NULL
Before	NULL
14.1	NULL
+	NULL
10.2	NULL
6,170	NULL
After	NULL
13.2	NULL
+	NULL
10.4	NULL
3N	NULL
,	NULL
17	NULL
,	NULL
Female	NULL
4.650	NULL
35.2	NULL
+	NULL
31.4	NULL
2/3	NULL
§	NULL
<	NULL
15	NULL
1°	NULL
Male	NULL
8,440	NULL
*	NULL
Mean	NULL
+	NULL
S.D	NULL
.	NULL

b	NULL
N	NULL
,	NULL
null	NULL
cell-derived	NULL
;	NULL
T	NULL
,	NULL
T-cell-derived	NULL
.	NULL

©	NULL
Immunological	NULL
characterization	NULL
was	NULL
not	NULL
performed	NULL
.	NULL

basis	NULL
of	NULL
morphological	NULL
criteria	NULL
and	NULL
labeling	NULL
index	NULL
(	NULL
19	NULL
,	NULL
26	NULL
,	NULL
35	NULL
)	NULL
.	NULL

It	NULL
has	NULL
been	NULL
suggested	NULL
that	NULL
,	NULL
during	NULL
the	NULL
maturation	NULL
process	NULL
of	NULL
leukemic	NULL
blasts	NULL
,	NULL
some	NULL
cells	NULL
proliferate	NULL
while	NULL
others	NULL
do	NULL
not	NULL
and	NULL
cells	NULL
may	NULL
die	NULL
at	NULL
any	NULL
stage	NULL
of	NULL
their	NULL
development	NULL
(	NULL
26	NULL
,	NULL
48	NULL
)	NULL
.	NULL

The	NULL
question	NULL
as	NULL
to	NULL
the	NULL
kind	NULL
of	NULL
cells	NULL
which	NULL
are	NULL
preferentially	NULL
released	NULL
from	NULL
bone	NULL
marrow	NULL
is	NULL
still	NULL
open	NULL
.	NULL

More	NULL
recently	NULL
,	NULL
Wagner	NULL
et	NULL
a/	NULL
.	NULL

(	NULL
48	NULL
,	NULL
49	NULL
)	NULL
pointed	NULL
out	NULL
that	NULL
each	NULL
of	NULL
the	NULL
various	NULL
types	NULL
of	NULL
ALL	NULL
(	NULL
``	NULL
'null	NULL
,	NULL
``	NULL
'	NULL
T-cell-derived	NULL
,	NULL
and	NULL
B-cell-derived	NULL
ALL	NULL
)	NULL
does	NULL
not	NULL
represent	NULL
a	NULL
uniform	NULL
type	NULL
of	NULL
neoplasia	NULL
with	NULL
an	NULL
identical	NULL
growth	NULL
pattern	NULL
.	NULL

Considering	NULL
all	NULL
the	NULL
factors	NULL
of	NULL
heterogeneity	NULL
which	NULL
exist	NULL
in	NULL
ALL	NULL
,	NULL
it	NULL
is	NULL
not	NULL
surprising	NULL
to	NULL
find	NULL
no	NULL
correlation	NULL
between	NULL
in	NULL
vivo	NULL
and	NULL
in	NULL
vitro	NULL
effects	NULL
of	NULL
glucocorticoids	NULL
.	NULL

Using	NULL
both	NULL
freshly	NULL
isolated	NULL
cells	NULL
and	NULL
a	NULL
whole-cell	NULL
binding	NULL
assay	NULL
to	NULL
minimize	NULL
technical	NULL
problems	NULL
,	NULL
we	NULL
failed	NULL
to	NULL
show	NULL
any	NULL
relationship	NULL
between	NULL
the	NULL
level	NULL
of	NULL
steroid	NULL
receptors	NULL
in	NULL
lymphoid	NULL
cells	NULL
and	NULL
the	NULL
in	NULL
vitro	NULL
actions	NULL
of	NULL
glucocorticoid	NULL
,	NULL
the	NULL
clinical	NULL
features	NULL
of	NULL
the	NULL
patients	NULL
investigated	NULL
,	NULL
or	NULL
the	NULL
in	NULL
vivo	NULL
response	NULL
.	NULL

The	NULL
only	NULL
significant	NULL
correlation	NULL
found	NULL
with	NULL
regard	NULL
to	NULL
the	NULL
steroid	NULL
effects	NULL
in	NULL
vitro	NULL
was	NULL
the	NULL
relationship	NULL
between	NULL
uridine	NULL
and	NULL
thymidine	NULL
incorporation	NULL
in	NULL
ALL	NULL
and	NULL
the	NULL
steroid-induced	NULL
inhibition	NULL
of	NULL
their	NULL
incorporation	NULL
.	NULL

This	NULL
suggests	NULL
,	NULL
as	NULL
previously	NULL
reviewed	NULL
(	NULL
2	NULL
,	NULL
9	NULL
)	NULL
,	NULL
that	NULL
the	NULL
effects	NULL
of	NULL
glucocorticoids	NULL
on	NULL
lymphoid	NULL
cells	NULL
greatly	NULL
depend	NULL
upon	NULL
the	NULL
state	NULL
of	NULL
the	NULL
cell	NULL
at	NULL
the	NULL
time	NULL
of	NULL
drug	NULL
exposure	NULL
.	NULL

We	NULL
therefore	NULL
conclude	NULL
that	NULL
steroid	NULL
receptor	NULL
determinations	NULL
in	NULL
human	NULL
circulating	NULL
leukemic	NULL
cells	NULL
are	NULL
not	NULL
sufficient	NULL
to	NULL
preclude	NULL
steroid	NULL
sensitivity	NULL
.	NULL

Using	NULL
pulse	NULL
cytophotometry	NULL
analysis	NULL
and	NULL
density	NULL
gradient	NULL
centrifugation	NULL
,	NULL
we	NULL
have	NULL
demonstrated	NULL
that	NULL
in	NULL
blood	NULL
samples	NULL
of	NULL
ALL	NULL
the	NULL
pattern	NULL
of	NULL
proliferative	NULL
activity	NULL
is	NULL
highly	NULL
variable	NULL
and	NULL
that	NULL
a	NULL
marked	NULL
cell	NULL
heterogeneity	NULL
exists	NULL
in	NULL
a	NULL
given	NULL
patient	NULL
and	NULL
between	NULL
different	NULL
patients	NULL
with	NULL
the	NULL
same	NULL
clinical	NULL
features	NULL
.	NULL

Furthermore	NULL
,	NULL
we	NULL
have	NULL
shown	NULL
that	NULL
the	NULL
degree	NULL
of	NULL
steroid	NULL
action	NULL
in	NULL
vitro	NULL
may	NULL
be	NULL
related	NULL
to	NULL
the	NULL
number	NULL
of	NULL
cells	NULL
in	NULL
S	NULL
phase	NULL
as	NULL
well	NULL
as	NULL
the	NULL
extent	NULL
of	NULL
spontaneous	NULL
cell	NULL
death	NULL
and	NULL
dexamethasone-induced	NULL
cell	NULL
death	NULL
.	NULL

It	NULL
should	NULL
be	NULL
mentioned	NULL
that	NULL
,	NULL
for	NULL
experimental	NULL
convenience	NULL
,	NULL
most	NULL
of	NULL
the	NULL
experiments	NULL
performed	NULL
in	NULL
order	NULL
to	NULL
determine	NULL
the	NULL
effects	NULL
of	NULL
glucocorticoids	NULL
on	NULL
leukemic	NULL
cells	NULL
in	NULL
vitro	NULL
were	NULL
with	NULL
WBC	NULL
instead	NULL
of	NULL
bone	NULL
marrow	NULL
cells	NULL
.	NULL

However	NULL
,	NULL
it	NULL
has	NULL
been	NULL
shown	NULL
that	NULL
peripheral	NULL
blood	NULL
cells	NULL
do	NULL
not	NULL
entirely	NULL
reflect	NULL
the	NULL
proliferative	NULL
activity	NULL
of	NULL
the	NULL
bone	NULL
marrow	NULL
(	NULL
20	NULL
,	NULL
35	NULL
)	NULL
.	NULL

Hillen	NULL
et	NULL
a/	NULL
.	NULL

JULY	NULL
1980	NULL
(	NULL
21	NULL
)	NULL
,	NULL
using	NULL
pulse	NULL
cytophotometry	NULL
analysis	NULL
,	NULL
have	NULL
investigated	NULL
the	NULL
short-term	NULL
and	NULL
long-term	NULL
effects	NULL
of	NULL
prednisone	NULL
treatment	NULL
on	NULL
blood	NULL
and	NULL
bone	NULL
marrow	NULL
cells	NULL
of	NULL
ALL	NULL
patients	NULL
.	NULL

They	NULL
found	NULL
a	NULL
considerable	NULL
decrease	NULL
in	NULL
S	NULL
phase	NULL
and	NULL
G	NULL
,	NULL
+	NULL
M	NULL
cell	NULL
in	NULL
bone	NULL
marrow	NULL
of	NULL
the	NULL
patients	NULL
after	NULL
3	NULL
days	NULL
of	NULL
treatment	NULL
,	NULL
while	NULL
bone	NULL
marrow	NULL
morphology	NULL
(	NULL
percentage	NULL
of	NULL
blasts	NULL
)	NULL
remained	NULL
almost	NULL
unchanged	NULL
.	NULL

In	NULL
most	NULL
patients	NULL
,	NULL
this	NULL
effect	NULL
was	NULL
accompanied	NULL
by	NULL
a	NULL
rapid	NULL
decline	NULL
in	NULL
the	NULL
number	NULL
of	NULL
lymphoblasts	NULL
in	NULL
the	NULL
peripheral	NULL
blood	NULL
.	NULL

After	NULL
1	NULL
or	NULL
2	NULL
weeks	NULL
of	NULL
daily	NULL
prednisone	NULL
treatment	NULL
,	NULL
they	NULL
found	NULL
an	NULL
increase	NULL
in	NULL
the	NULL
proportion	NULL
of	NULL
bone	NULL
marrow	NULL
cells	NULL
in	NULL
the	NULL
S	NULL
and	NULL
G	NULL
;	NULL
+	NULL
M	NULL
phases	NULL
in	NULL
all	NULL
patients	NULL
,	NULL
while	NULL
the	NULL
percentage	NULL
of	NULL
lymphoblasts	NULL
in	NULL
the	NULL
bone	NULL
marrow	NULL
diminished	NULL
and	NULL
the	NULL
normal	NULL
hemopoietic	NULL
cells	NULL
reappeared	NULL
.	NULL

They	NULL
suggested	NULL
that	NULL
glucocorticoids	NULL
cause	NULL
a	NULL
selective	NULL
lysis	NULL
of	NULL
lymphoblasts	NULL
,	NULL
independent	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
,	NULL
while	NULL
the	NULL
development	NULL
of	NULL
normal	NULL
hemopoiesis	NULL
is	NULL
not	NULL
disturbed	NULL
.	NULL

This	NULL
is	NULL
in	NULL
agreement	NULL
with	NULL
the	NULL
rapid	NULL
disappearance	NULL
of	NULL
mainly	NULL
nonproliferating	NULL
lymphoblasts	NULL
from	NULL
the	NULL
peripheral	NULL
blood	NULL
during	NULL
prednisone	NULL
treatment	NULL
demonstrated	NULL
by	NULL
Ernst	NULL
and	NULL
Killmann	NULL
(	NULL
17	NULL
)	NULL
.	NULL

They	NULL
also	NULL
suggested	NULL
that	NULL
,	NULL
beside	NULL
the	NULL
lytic	NULL
effect	NULL
,	NULL
prednisone	NULL
may	NULL
also	NULL
have	NULL
an	NULL
effect	NULL
on	NULL
the	NULL
mitotic	NULL
cycle	NULL
which	NULL
could	NULL
explain	NULL
the	NULL
decreased	NULL
percentages	NULL
of	NULL
cells	NULL
in	NULL
the	NULL
S	NULL
and	NULL
G	NULL
+	NULL
M	NULL
phases	NULL
during	NULL
the	NULL
first	NULL
days	NULL
of	NULL
treatment	NULL
.	NULL

Such	NULL
inhibition	NULL
of	NULL
the	NULL
passage	NULL
of	NULL
lymphoblasts	NULL
from	NULL
G	NULL
,	NULL
to	NULL
S	NULL
has	NULL
already	NULL
been	NULL
demonstrated	NULL
(	NULL
17	NULL
,	NULL
29	NULL
)	NULL
.	NULL

Bone	NULL
marrow	NULL
cells	NULL
may	NULL
represent	NULL
a	NULL
more	NULL
appropriate	NULL
tissue	NULL
for	NULL
the	NULL
study	NULL
of	NULL
glucocorticoid	NULL
action	NULL
,	NULL
and	NULL
comparison	NULL
with	NULL
blood	NULL
cells	NULL
would	NULL
be	NULL
of	NULL
great	NULL
interest	NULL
.	NULL

Depending	NULL
on	NULL
the	NULL
nature	NULL
of	NULL
the	NULL
leukemic	NULL
cells	NULL
,	NULL
the	NULL
effects	NULL
of	NULL
glucocorticoids	NULL
in	NULL
vitro	NULL
may	NULL
differ	NULL
,	NULL
inhibiting	NULL
DNA	NULL
synthesis	NULL
in	NULL
a	NULL
given	NULL
population	NULL
of	NULL
blasts	NULL
without	NULL
affecting	NULL
their	NULL
viability	NULL
and	NULL
inducing	NULL
cell	NULL
lysis	NULL
or	NULL
accelerating	NULL
programmed	NULL
cell	NULL
death	NULL
in	NULL
another	NULL
population	NULL
(	NULL
34	NULL
,	NULL
42	NULL
)	NULL
.	NULL

Finally	NULL
,	NULL
there	NULL
are	NULL
a	NULL
number	NULL
of	NULL
additional	NULL
problems	NULL
which	NULL
have	NULL
not	NULL
been	NULL
mentioned	NULL
,	NULL
such	NULL
as	NULL
the	NULL
effects	NULL
of	NULL
glucocorticoids	NULL
on	NULL
leukocyte	NULL
and	NULL
vascular	NULL
function	NULL
and	NULL
on	NULL
the	NULL
general	NULL
hormonal	NULL
balance	NULL
to	NULL
which	NULL
tumors	NULL
are	NULL
exposed	NULL
(	NULL
5	NULL
)	NULL
.	NULL

Such	NULL
in	NULL
vivo	NULL
perturbations	NULL
induced	NULL
by	NULL
glucocorticoids	NULL
could	NULL
influence	NULL
the	NULL
evolution	NULL
of	NULL
leukemia	NULL
.	NULL

Indeed	NULL
,	NULL
it	NULL
has	NULL
been	NULL
demonstrated	NULL
recently	NULL
that	NULL
the	NULL
effects	NULL
of	NULL
glucocorticoids	NULL
on	NULL
lymphocytes	NULL
are	NULL
more	NULL
indirect	NULL
(	NULL
suppressing	NULL
the	NULL
production	NULL
of	NULL
T-cell	NULL
growth	NULL
factor	NULL
by	NULL
some	NULL
cells	NULL
)	NULL
than	NULL
direct	NULL
(	NULL
at	NULL
the	NULL
level	NULL
of	NULL
the	NULL
activated	NULL
lymphocytes	NULL
)	NULL
(	NULL
18	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
the	NULL
experimental	NULL
in	NULL
vitro	NULL
con	NULL
2607	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1980	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

F.	NULL
Homo	NULL
et	NULL
al	NULL
.	NULL

ditions	NULL
do	NULL
not	NULL
correspond	NULL
to	NULL
the	NULL
in	NULL
vivo	NULL
situation	NULL
.	NULL

In	NULL
vivo	NULL
,	NULL
the	NULL
steroid	NULL
could	NULL
not	NULL
only	NULL
affect	NULL
the	NULL
lymphoid	NULL
tissue	NULL
directly	NULL
but	NULL
also	NULL
disturb	NULL
the	NULL
ionic	NULL
and/or	NULL
hormonal	NULL
hemopoietic	NULL
microen-vironment	NULL
.	NULL

in	NULL
vitro	NULL
studies	NULL
would	NULL
therefore	NULL
not	NULL
encompass	NULL
these	NULL
possible	NULL
synergistic-antagonistic	NULL
factors	NULL
of	NULL
steroid	NULL
action	NULL
.	NULL

ACKNOWLEDGMENTS	NULL
We	NULL
gratefully	NULL
acknowledge	NULL
J.	NULL
Hatzfeld	NULL
and	NULL
C.	NULL
Evrard	NULL
(	NULL
Institut	NULL
de	NULL
Biologie	NULL
Moléculaire	NULL
,	NULL
2	NULL
place	NULL
Jussieu	NULL
,	NULL
75005	NULL
Paris	NULL
,	NULL
France	NULL
)	NULL
for	NULL
the	NULL
use	NULL
of	NULL
the	NULL
Cytofluorograf	NULL
and	NULL
J.	NULL
Simon	NULL
for	NULL
her	NULL
excellent	NULL
technical	NULL
assistance	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Baumer	NULL
,	NULL
J.	NULL
H.	NULL
,	NULL
and	NULL
Mott	NULL
,	NULL
M.	NULL
G.	NULL
Sex	NULL
and	NULL
prognosis	NULL
in	NULL
childhood	NULL
acute	NULL
lymphoblastic	NULL
leukemia	NULL
.	NULL

Lancet	NULL
,	NULL
2	NULL
:	NULL
128-129	NULL
,	NULL
1978	NULL
.	NULL

2	NULL
.	NULL

Baxter	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
and	NULL
Harris	NULL
,	NULL
A.	NULL
W.	NULL
Mechanism	NULL
of	NULL
glucocorticoid	NULL
action	NULL
:	NULL
general	NULL
features	NULL
with	NULL
reference	NULL
to	NULL
steroid-mediated	NULL
immunosuppression	NULL
.	NULL

Transplant	NULL
.	NULL

Proc	NULL
.	NULL

,	NULL
7	NULL
:	NULL
55-65	NULL
,	NULL
1975	NULL
.	NULL

3	NULL
.	NULL

Bernard	NULL
,	NULL
J.	NULL
,	NULL
Levy	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
and	NULL
Varet	NULL
,	NULL
B.	NULL
Les	NULL
leucémies	NULL
aigues	NULL
.	NULL

in	NULL
:	NULL
Hematologie	NULL
,	NULL
Vol	NULL
.	NULL

2	NULL
,	NULL
p.	NULL
1848	NULL
.	NULL

Paris	NULL
:	NULL
Flammarion	NULL
Medecine	NULL
Science	NULL
,	NULL
1976	NULL
.	NULL

4	NULL
.	NULL

Bird	NULL
,	NULL
C.	NULL
C.	NULL
Clinical	NULL
classification	NULL
of	NULL
leukaemia	NULL
and	NULL
lymphoma	NULL
in	NULL
relation	NULL
to	NULL
glucocorticoid	NULL
therapy	NULL
.	NULL

in	NULL
:	NULL
Glucocorticoid	NULL
Action	NULL
and	NULL
Leukaemia	NULL
.	NULL

p.	NULL
123	NULL
.	NULL

Cardiff	NULL
,	NULL
U.	NULL
K.	NULL
;	NULL
:	NULL
Alpha	NULL
Omega	NULL
Alpha	NULL
Publishing	NULL
Ltd.	NULL
,	NULL
1979	NULL
.	NULL

5	NULL
.	NULL

Bird	NULL
,	NULL
C.	NULL
C.	NULL
,	NULL
Wadell	NULL
,	NULL
A.	NULL
W.	NULL
,	NULL
Robertson	NULL
,	NULL
A.	NULL
M.	NULL
G.	NULL
,	NULL
Currie	NULL
,	NULL
A.	NULL
R.	NULL
,	NULL
Steel	NULL
,	NULL
C.	NULL
M.	NULL
,	NULL
and	NULL
Evans	NULL
,	NULL
J.	NULL
Cytoplasmic	NULL
receptor	NULL
levels	NULL
and	NULL
glucocorticoid	NULL
response	NULL
in	NULL
human	NULL
lymphoblastoid	NULL
cell	NULL
lines	NULL
.	NULL

Br	NULL
.	NULL

J	NULL
.	NULL

Cancer	NULL
,	NULL
33	NULL
:	NULL
700-707	NULL
,	NULL
1976	NULL
.	NULL

6	NULL
.	NULL

Boyum	NULL
,	NULL
A	NULL
.	NULL

Separation	NULL
of	NULL
lymphocytes	NULL
and	NULL
erythrocytes	NULL
by	NULL
centrifugation	NULL
.	NULL

Scand	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Lab	NULL
.	NULL

Invest	NULL
.	NULL

,	NULL
Suppl	NULL
.	NULL

97	NULL
,	NULL
1-109	NULL
,	NULL
1968	NULL
.	NULL

7	NULL
.	NULL

Brouet	NULL
,	NULL
J.	NULL
C.	NULL
,	NULL
and	NULL
Seligmann	NULL
,	NULL
M.	NULL
The	NULL
immunological	NULL
classification	NULL
of	NULL
acute	NULL
lymphoblastic	NULL
leukaemias	NULL
.	NULL

Cancer	NULL
(	NULL
Phila	NULL
.	NULL
)	NULL

,	NULL
42	NULL
:	NULL
817-827	NULL
,	NULL
1978	NULL
.	NULL

8	NULL
.	NULL

Chessels	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
Hardisty	NULL
,	NULL
R.	NULL
M.	NULL
,	NULL
and	NULL
Rapson	NULL
,	NULL
N.	NULL
T.	NULL
Acute	NULL
lymphoblastic	NULL
leukaemia	NULL
in	NULL
children	NULL
:	NULL
classification	NULL
and	NULL
prognosis	NULL
.	NULL

Lancet	NULL
,	NULL
2	NULL
:	NULL
1307-1309	NULL
,	NULL
1977	NULL
.	NULL

9	NULL
.	NULL

Claman	NULL
,	NULL
H.	NULL
N.	NULL
Corticosteroids	NULL
and	NULL
lymphoid	NULL
cells	NULL
.	NULL

N.	NULL
Engl	NULL
.	NULL

J	NULL
.	NULL

Med	NULL
.	NULL

,	NULL
287	NULL
:	NULL
388-397	NULL
,	NULL
1972	NULL
.	NULL

10	NULL
.	NULL

Colley	NULL
,	NULL
D.	NULL
G.	NULL
,	NULL
Shih	NULL
Yu	NULL
,	NULL
A.	NULL
Y.	NULL
,	NULL
and	NULL
Waksman	NULL
,	NULL
B.	NULL
H.	NULL
Cellular	NULL
differentiation	NULL
in	NULL
the	NULL
thymus	NULL
.	NULL

III	NULL
.	NULL

Surface	NULL
properties	NULL
of	NULL
rat	NULL
thymus	NULL
and	NULL
lymph	NULL
node	NULL
cells	NULL
separated	NULL
on	NULL
density	NULL
gradients	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

,	NULL
132	NULL
:	NULL
1107-1121	NULL
,	NULL
1970	NULL
.	NULL

11	NULL
.	NULL

Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
,	NULL
Smith	NULL
,	NULL
K.	NULL
A.	NULL
,	NULL
and	NULL
Munck	NULL
,	NULL
A.	NULL
Glucocorticoid	NULL
receptors	NULL
and	NULL
in	NULL
vivo	NULL
sensitivity	NULL
of	NULL
cells	NULL
from	NULL
patients	NULL
with	NULL
leukaemia	NULL
and	NULL
lymphoma	NULL
:	NULL
a	NULL
reassessment	NULL
.	NULL

in	NULL
:	NULL
Glucocorticoid	NULL
Action	NULL
and	NULL
Leukaemia	NULL
,	NULL
p.	NULL
191	NULL
.	NULL

Cardiff	NULL
,	NULL
U.	NULL
K.	NULL
:	NULL
Alpha	NULL
Omega	NULL
Alpha	NULL
Publishing	NULL
Ltd.	NULL
,	NULL
1979	NULL
.	NULL

12	NULL
.	NULL

Davis	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Rubin	NULL
,	NULL
A.	NULL
D.	NULL
Cell	NULL
surface	NULL
markers	NULL
in	NULL
the	NULL
characterization	NULL
of	NULL
human	NULL
lymphoreticular	NULL
diseases	NULL
.	NULL

in	NULL
:	NULL
The	NULL
Leukaemia	NULL
cell	NULL
,	NULL
p.	NULL
127	NULL
.	NULL

West	NULL
Palm	NULL
Beach	NULL
,	NULL
Fla	NULL
:	NULL
CRC	NULL
Press	NULL
,	NULL
1979	NULL
.	NULL

13	NULL
.	NULL

Duval	NULL
,	NULL
D.	NULL
,	NULL
Dausse	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
and	NULL
Dardenne	NULL
,	NULL
M.	NULL
Glucocorticoid	NULL
receptors	NULL
in	NULL
corticosensitive	NULL
and	NULL
corticoresistant	NULL
thymocyte	NULL
subpopulations	NULL
.	NULL

I	NULL
.	NULL

Characterization	NULL
of	NULL
glucocorticoid	NULL
receptors	NULL
and	NULL
isolation	NULL
of	NULL
a	NULL
corticoresistant	NULL
subpopulation	NULL
.	NULL

Biochim	NULL
.	NULL

Biophys	NULL
.	NULL

Acta	NULL
,	NULL
451	NULL
;	NULL
82-91	NULL
,	NULL
1976	NULL
.	NULL

14	NULL
.	NULL

Duval	NULL
,	NULL
D.	NULL
,	NULL
and	NULL
Homo	NULL
,	NULL
F.	NULL
Prognostic	NULL
value	NULL
of	NULL
steroid	NULL
receptor	NULL
determination	NULL
in	NULL
leukemia	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

,	NULL
38	NULL
:	NULL
4263-4267	NULL
,	NULL
1978	NULL
.	NULL

15	NULL
.	NULL

Duval	NULL
,	NULL
D.	NULL
,	NULL
Homo	NULL
,	NULL
F.	NULL
,	NULL
Fournier	NULL
,	NULL
C.	NULL
,	NULL
and	NULL
Dausse	NULL
,	NULL
J.	NULL
P.	NULL
Glucocorticoid	NULL
receptors	NULL
in	NULL
mouse	NULL
spleen	NULL
cell	NULL
subpopulations	NULL
.	NULL

Cell	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
46	NULL
:	NULL
1-11	NULL
,	NULL
1979	NULL
.	NULL

16	NULL
.	NULL

Edelman	NULL
,	NULL
I.	NULL
S.	NULL
Mechanism	NULL
of	NULL
action	NULL
of	NULL
steroid	NULL
hormones	NULL
.	NULL

J.	NULL
Steroid	NULL
Biochem	NULL
.	NULL

,	NULL
6	NULL
:	NULL
147-159	NULL
,	NULL
1975	NULL
.	NULL

17	NULL
.	NULL

Emst	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Killmann	NULL
,	NULL
S.	NULL
A.	NULL
Perturbation	NULL
of	NULL
generation	NULL
cycle	NULL
of	NULL
human	NULL
leukemic	NULL
blast	NULL
cells	NULL
by	NULL
cytostatic	NULL
therapy	NULL
in	NULL
vivo	NULL
:	NULL
effect	NULL
of	NULL
corticosteroids	NULL
.	NULL

Blood	NULL
,	NULL
36	NULL
:	NULL
689-696	NULL
,	NULL
1970	NULL
.	NULL

18	NULL
.	NULL

Gillis	NULL
,	NULL
S.	NULL
,	NULL
Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
,	NULL
and	NULL
Smith	NULL
,	NULL
K.	NULL
A.	NULL
Glucocorticoid-induced	NULL
inhibition	NULL
of	NULL
T-cell	NULL
growth	NULL
factor	NULL
production	NULL
.	NULL

I	NULL
.	NULL

The	NULL
effect	NULL
on	NULL
mitogen-induced	NULL
lymphocyte	NULL
proliferation	NULL
.	NULL

J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
123	NULL
;	NULL
1624-1631	NULL
,	NULL
1979	NULL
.	NULL

19	NULL
.	NULL

Greenberg	NULL
,	NULL
M.	NULL
L.	NULL
Cellular	NULL
kinetics	NULL
in	NULL
the	NULL
leukaemias	NULL
.	NULL

in	NULL
:	NULL
The	NULL
Leukaemia	NULL
Cell	NULL
,	NULL
p.	NULL
89	NULL
.	NULL

West	NULL
Palm	NULL
Beach	NULL
,	NULL
Fla	NULL
:	NULL
CRC	NULL
Press	NULL
,	NULL
1979	NULL
.	NULL

20	NULL
.	NULL

Hillen	NULL
,	NULL
H.	NULL
P.	NULL
F.	NULL
,	NULL
Wessels	NULL
,	NULL
J.	NULL
M.	NULL
C.	NULL
,	NULL
and	NULL
Haanen	NULL
,	NULL
C.	NULL
A.	NULL
M.	NULL
Principles	NULL
of	NULL
pulse	NULL
cytophotometry	NULL
and	NULL
the	NULL
application	NULL
in	NULL
DNA	NULL
measurements	NULL
.	NULL

in	NULL
:	NULL
Cell	NULL
Profif-eration	NULL
Patterns	NULL
in	NULL
Acute	NULL
Leukaemia	NULL
Monitored	NULL
by	NULL
Pulse-Cytophotometry	NULL
,	NULL
p.	NULL
23	NULL
.	NULL

Ghent	NULL
,	NULL
Belgium	NULL
:	NULL
European	NULL
Press	NULL
Medikon	NULL
,	NULL
1975	NULL
.	NULL

21	NULL
.	NULL

Hillen	NULL
,	NULL
H.	NULL
P.	NULL
F.	NULL
,	NULL
Wessels	NULL
,	NULL
J.	NULL
M.	NULL
C.	NULL
,	NULL
and	NULL
Haanen	NULL
,	NULL
C.	NULL
A.	NULL
M.	NULL
Bone-marrow	NULL
proliferation	NULL
patterns	NULL
and	NULL
cell	NULL
kinetic	NULL
effects	NULL
of	NULL
prednisone	NULL
in	NULL
acute	NULL
lymphoblastic	NULL
monitored	NULL
by	NULL
pulse-cytophotometry	NULL
.	NULL

in	NULL
:	NULL
Cell	NULL
Proliferation	NULL
Patterns	NULL
in	NULL
2608	NULL
©	NULL
22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

44	NULL
.	NULL

45	NULL
.	NULL

46	NULL
.	NULL

47	NULL
.	NULL

48	NULL
.	NULL

49	NULL
.	NULL

Acute	NULL
Leukaemia	NULL
Monitored	NULL
by	NULL
Pulse	NULL
Cytophotometry	NULL
,	NULL
p.	NULL
61	NULL
.	NULL

Ghent	NULL
,	NULL
Belgium	NULL
:	NULL
European	NULL
Press	NULL
Medikon	NULL
,	NULL
1975	NULL
.	NULL

Homo	NULL
,	NULL
F.	NULL
,	NULL
Duval	NULL
,	NULL
D.	NULL
,	NULL
Hatzfeld	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
Evrard	NULL
,	NULL
C.	NULL
Glucocorticoid	NULL
sensitive	NULL
and	NULL
resistant	NULL
cell	NULL
populations	NULL
in	NULL
mouse	NULL
thymus	NULL
.	NULL

J.	NULL
Steroid	NULL
Biochem	NULL
.	NULL

,	NULL
13	NULL
:	NULL
135-143	NULL
,	NULL
1980.	NULL
.	NULL

Homo	NULL
,	NULL
F.	NULL
,	NULL
Duval	NULL
,	NULL
D.	NULL
,	NULL
and	NULL
Meyer	NULL
,	NULL
P.	NULL
Etude	NULL
de	NULL
la	NULL
liaison	NULL
de	NULL
la	NULL
dexamethasone	NULL
tritiée	NULL
dans	NULL
les	NULL
lymphocytes	NULL
de	NULL
sujets	NULL
normaux	NULL
et	NULL
leucémiques	NULL
.	NULL

C.	NULL
R.	NULL
Acad	NULL
Sci	NULL
.	NULL

Paris	NULL
,	NULL
280	NULL
D	NULL
:	NULL
1923-1926	NULL
,	NULL
1975	NULL
.	NULL

Homo	NULL
,	NULL
F.	NULL
,	NULL
Duval	NULL
,	NULL
D.	NULL
,	NULL
Meyer	NULL
,	NULL
P.	NULL
,	NULL
Belas	NULL
,	NULL
F.	NULL
,	NULL
Debre	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Binet	NULL
,	NULL
J.	NULL
L.	NULL
Chronic	NULL
lymphatic	NULL
leukaemia	NULL
:	NULL
cellular	NULL
effects	NULL
of	NULL
glucocorticoids	NULL
in	NULL
vitro	NULL
.	NULL

Br	NULL
.	NULL

J	NULL
.	NULL

Hae-matol	NULL
.	NULL

,	NULL
38	NULL
:	NULL
491-499	NULL
,	NULL
1978	NULL
.	NULL

Homo	NULL
,	NULL
F.	NULL
,	NULL
Duval	NULL
,	NULL
D.	NULL
,	NULL
Thierry	NULL
,	NULL
C.	NULL
,	NULL
and	NULL
Serrou	NULL
,	NULL
B	NULL
.	NULL

Human	NULL
lymphocyte	NULL
subpop-ulations	NULL
:	NULL
effects	NULL
of	NULL
glucocorticoids	NULL
in	NULL
vifro	NULL
.	NULL

J.	NULL
Steroid	NULL
Biochem	NULL
.	NULL

,	NULL
10	NULL
:	NULL
609-613	NULL
,	NULL
1979	NULL
.	NULL

Killmann	NULL
,	NULL
S.	NULL
A.	NULL
Proliferative	NULL
activity	NULL
of	NULL
blast	NULL
cells	NULL
in	NULL
leukemia	NULL
and	NULL
myelofi-brosis	NULL
.	NULL

Morphological	NULL
differences	NULL
between	NULL
proliferating	NULL
and	NULL
non-proliferat-ing	NULL
blast-cells	NULL
.	NULL

Acta	NULL
Med	NULL
.	NULL

Scand	NULL
.	NULL

,	NULL
178	NULL
:	NULL
263-280	NULL
,	NULL
1965	NULL
.	NULL

Komuro	NULL
,	NULL
K.	NULL
,	NULL
and	NULL
Boyse	NULL
,	NULL
E.	NULL
A.	NULL
in	NULL
vitro	NULL
demonstration	NULL
of	NULL
thymic	NULL
hormone	NULL
in	NULL
the	NULL
mouse	NULL
by	NULL
conversion	NULL
of	NULL
precursor	NULL
cells	NULL
into	NULL
lymphocytes	NULL
.	NULL

Lancet	NULL
,	NULL
1	NULL
:	NULL
740-743	NULL
,	NULL
1973	NULL
.	NULL

Konior	NULL
Yarbro	NULL
,	NULL
G.	NULL
S.	NULL
,	NULL
Lippman	NULL
,	NULL
M.	NULL
E.	NULL
,	NULL
Johnson	NULL
,	NULL
G.	NULL
E.	NULL
,	NULL
and	NULL
Leventhal	NULL
,	NULL
B.	NULL
J.	NULL
Glucocorticoid	NULL
receptors	NULL
in	NULL
subpopulations	NULL
of	NULL
childhood	NULL
acute	NULL
tymphocytic	NULL
leukemia	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

,	NULL
37	NULL
:	NULL
2688-2695	NULL
,	NULL
1977	NULL
.	NULL

Lampkin	NULL
,	NULL
B.	NULL
C.	NULL
,	NULL
Nagao	NULL
,	NULL
T.	NULL
,	NULL
and	NULL
Mauer	NULL
,	NULL
A.	NULL
M.	NULL
Drug	NULL
effect	NULL
in	NULL
acute	NULL
leukemia	NULL
.	NULL

48	NULL
:	NULL
1124-1130	NULL
,	NULL
1979.	NULL
c	NULL
.	NULL

Lippman	NULL
,	NULL
M..E.	NULL
,	NULL
Halterman	NULL
,	NULL
R.	NULL
H.	NULL
,	NULL
Leventhal	NULL
,	NULL
B.	NULL
G.	NULL
,	NULL
Perry	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Thompson	NULL
,	NULL
E.	NULL
B.	NULL
Glucocorticoid-binding	NULL
proteins	NULL
in	NULL
human	NULL
lymphoblastic	NULL
leukemic	NULL
blast	NULL
cells	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

,	NULL
52	NULL
:	NULL
1715-1725	NULL
,	NULL
1973	NULL
.	NULL

Lippman	NULL
,	NULL
M.	NULL
E.	NULL
,	NULL
Konior-Yarbro	NULL
,	NULL
G.	NULL
S.	NULL
,	NULL
and	NULL
Leventhal	NULL
,	NULL
B.	NULL
G.	NULL
Glucocorticoid	NULL
receptors	NULL
in	NULL
normal	NULL
and	NULL
leukaemic	NULL
human	NULL
leucocytes	NULL
.	NULL

In	NULL
:	NULL
Glucocorticold	NULL
Action	NULL
and	NULL
Leukaemia	NULL
,	NULL
p.	NULL
175	NULL
.	NULL

Cardiff	NULL
,	NULL
U.	NULL
K.	NULL
:	NULL
Alpha	NULL
Omega	NULL
Alpha	NULL
Publishing	NULL
Ltd.	NULL
,	NULL
1979	NULL
.	NULL

Lippman	NULL
,	NULL
M.	NULL
E.	NULL
,	NULL
Perry	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Thompson	NULL
,	NULL
E.	NULL
B.	NULL
Cytoplasmic	NULL
glucocorticoid-binding	NULL
proteins	NULL
in	NULL
glucocorticoid-unresponsive	NULL
human	NULL
and	NULL
mouse	NULL
leukemic	NULL
cell	NULL
lines	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

,	NULL
34	NULL
:	NULL
1572-1576	NULL
,	NULL
1974	NULL
.	NULL

Lippman	NULL
,	NULL
M.	NULL
E.	NULL
,	NULL
Perry	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Thompson	NULL
,	NULL
E.	NULL
B.	NULL
Glucocorticoid	NULL
binding	NULL
proteins	NULL
in	NULL
myeloblasts	NULL
of	NULL
acute	NULL
myelogenous	NULL
leukemia	NULL
.	NULL

Am	NULL
.	NULL

J	NULL
.	NULL

Med	NULL
.	NULL

,	NULL
59	NULL
:	NULL
224-227	NULL
,	NULL
1975.	NULL
.	NULL

Lockshin	NULL
,	NULL
R.	NULL
A.	NULL
,	NULL
and	NULL
Beaulaton	NULL
,	NULL
J.	NULL
Programmed	NULL
cell	NULL
death	NULL
.	NULL

Life	NULL
Sci	NULL
.	NULL

,	NULL
15	NULL
:	NULL
1549-1565	NULL
,	NULL
1975	NULL
.	NULL

Mauer	NULL
,	NULL
A.	NULL
M.	NULL
,	NULL
and	NULL
Fisher	NULL
,	NULL
V.	NULL
Comparison	NULL
of	NULL
the	NULL
proliferative	NULL
capacity	NULL
of	NULL
acute	NULL
leukaemia	NULL
cells	NULL
in	NULL
bone-marrow	NULL
and	NULL
blood	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

,	NULL
193	NULL
:	NULL
1085-1086	NULL
,	NULL
1962	NULL
.	NULL

Munck	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Leung	NULL
,	NULL
K.	NULL
Glucocorticoid	NULL
receptors	NULL
and	NULL
mechanism	NULL
of	NULL
action	NULL
.	NULL

in	NULL
:	NULL
Receptors	NULL
and	NULL
Mechanism	NULL
of	NULL
Action	NULL
of	NULL
Steroid	NULL
Hormones	NULL
,	NULL
Part	NULL
2	NULL
,	NULL
p.	NULL
311	NULL
.	NULL

New	NULL
York	NULL
:	NULL
Marcel	NULL
Dekker	NULL
,	NULL
Inc.	NULL
,	NULL
1977	NULL
.	NULL

Raff	NULL
,	NULL
M.	NULL
C.	NULL
Surface	NULL
antigenic	NULL
markers	NULL
for	NULL
distinguishing	NULL
T	NULL
and	NULL
B	NULL
lymphocytes	NULL
in	NULL
mice	NULL
.	NULL

Transplant	NULL
.	NULL

Rev	NULL
.	NULL

,	NULL
6	NULL
:	NULL
52-80	NULL
,	NULL
1971.	NULL
.	NULL

Sabolovic	NULL
,	NULL
D.	NULL
,	NULL
and	NULL
Dumont	NULL
,	NULL
F.	NULL
Separation	NULL
and	NULL
characterization	NULL
of	NULL
cell	NULL
subpopulations	NULL
in	NULL
the	NULL
thymus	NULL
.	NULL

Immunology	NULL
,	NULL
24	NULL
:	NULL
601-606	NULL
,	NULL
1973	NULL
.	NULL

Saunders	NULL
,	NULL
E.	NULL
F.	NULL
,	NULL
Lampkin	NULL
,	NULL
B.	NULL
C.	NULL
,	NULL
and	NULL
Mauer	NULL
,	NULL
A.	NULL
M.	NULL
Variation	NULL
of	NULL
proliferative	NULL
activity	NULL
in	NULL
leukemic	NULL
cell	NULL
populations	NULL
of	NULL
patients	NULL
with	NULL
acute	NULL
leukemia	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

,	NULL
46	NULL
:	NULL
1356-1363	NULL
,	NULL
1967	NULL
.	NULL

Scatchard	NULL
,	NULL
G.	NULL
The	NULL
attraction	NULL
of	NULL
proteins	NULL
for	NULL
small	NULL
molecules	NULL
and	NULL
ions	NULL
.	NULL

Ann	NULL
.	NULL

N.	NULL
Y.	NULL
Acad	NULL
.	NULL

Sci	NULL
.	NULL

,	NULL
51	NULL
:	NULL
660-672	NULL
,	NULL
1949	NULL
.	NULL

Sen	NULL
,	NULL
L.	NULL
,	NULL
and	NULL
Borella	NULL
,	NULL
L.	NULL
Clinical	NULL
importance	NULL
of	NULL
lymphoblasts	NULL
with	NULL
T	NULL
markers	NULL
in	NULL
childhood	NULL
acute	NULL
leukemia	NULL
.	NULL

N.	NULL
Engl	NULL
.	NULL

J	NULL
.	NULL

Med	NULL
.	NULL

,	NULL
292	NULL
:	NULL
828-832	NULL
,	NULL
1975	NULL
.	NULL

Shortman	NULL
,	NULL
K.	NULL
,	NULL
and	NULL
Jackson	NULL
,	NULL
H.	NULL
The	NULL
differentiation	NULL
of	NULL
T-lymphocytes	NULL
1	NULL
.	NULL

Proliferation	NULL
kinetic	NULL
and	NULL
interrelationships	NULL
of	NULL
subpopulations	NULL
of	NULL
mouse	NULL
thymus	NULL
cells	NULL
.	NULL

Cell	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
12	NULL
;	NULL
230-246	NULL
,	NULL
1974	NULL
.	NULL

Shortman	NULL
,	NULL
K.	NULL
,	NULL
Von	NULL
Boehmer	NULL
,	NULL
H.	NULL
,	NULL
Lipp	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
Hopper	NULL
,	NULL
K.	NULL
Subpopulations	NULL
of	NULL
T-lymphocytes	NULL
.	NULL

Physical	NULL
separation	NULL
,	NULL
functional	NULL
specialization	NULL
and	NULL
differentiation	NULL
pathways	NULL
of	NULL
sub-sets	NULL
of	NULL
thymocytes	NULL
and	NULL
thymus-dependent	NULL
peripheral	NULL
lymphocytes	NULL
.	NULL

Transplant	NULL
.	NULL

Rev	NULL
.	NULL

,	NULL
25	NULL
:	NULL
163-210	NULL
,	NULL
1975	NULL
.	NULL

Sibley	NULL
,	NULL
C.	NULL
H.	NULL
,	NULL
and	NULL
Tomkins	NULL
,	NULL
G.	NULL
M.	NULL
Mechanisms	NULL
of	NULL
steroid	NULL
resistance	NULL
.	NULL

Cell	NULL
,	NULL
2	NULL
:	NULL
221-227	NULL
,	NULL
1974	NULL
.	NULL

Sloman	NULL
,	NULL
J.	NULL
C.	NULL
,	NULL
and	NULL
Bell	NULL
,	NULL
P.	NULL
Glucocorticoids	NULL
and	NULL
myeloid	NULL
leukaemia	NULL
.	NULL

in	NULL
:	NULL
Glucocorticoid	NULL
Action	NULL
and	NULL
Leukaemia	NULL
,	NULL
p.	NULL
161	NULL
.	NULL

Cardiff	NULL
,	NULL
U.	NULL
K.	NULL
;	NULL
:	NULL
Alpha	NULL
Omega	NULL
Alpha	NULL
Publishing	NULL
Ltd.	NULL
,	NULL
1979	NULL
.	NULL

Thompson	NULL
,	NULL
E.	NULL
B	NULL
.	NULL

Report	NULL
on	NULL
the	NULL
international	NULL
union	NULL
against	NULL
cancer	NULL
workshop	NULL
on	NULL
steroid	NULL
receptors	NULL
in	NULL
leukaemia	NULL
.	NULL

Cancer	NULL
Treat	NULL
.	NULL

Rep.	NULL
,	NULL
63	NULL
:	NULL
189-195	NULL
,	NULL
1979	NULL
.	NULL

Tsukimoto	NULL
,	NULL
I.	NULL
,	NULL
Wong	NULL
,	NULL
K.	NULL
Y.	NULL
,	NULL
and	NULL
Lampkin	NULL
,	NULL
B.	NULL
C.	NULL
Surface	NULL
markers	NULL
and	NULL
prognostic	NULL
factors	NULL
in	NULL
acute	NULL
lymphoblastic	NULL
leukaemia	NULL
.	NULL

N.	NULL
Engl	NULL
.	NULL

J	NULL
.	NULL

Med	NULL
.	NULL

,	NULL
294	NULL
:	NULL
245-248	NULL
,	NULL
1976	NULL
.	NULL

Wagner	NULL
,	NULL
H.	NULL
P.	NULL
,	NULL
Cottier	NULL
,	NULL
H.	NULL
,	NULL
and	NULL
Cronkite	NULL
,	NULL
E.	NULL
P.	NULL
Variability	NULL
of	NULL
proliferative	NULL
patients	NULL
in	NULL
acute	NULL
lymphoid	NULL
leukemia	NULL
of	NULL
children	NULL
.	NULL

Blood	NULL
,	NULL
39	NULL
:	NULL
176-186	NULL
,	NULL
1972	NULL
.	NULL

Wagner	NULL
,	NULL
H.	NULL
P.	NULL
,	NULL
Giesen	NULL
,	NULL
L.	NULL
,	NULL
Muller	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
Cottier	NULL
,	NULL
H.	NULL
Diversity	NULL
in	NULL
proliferative	NULL
patterns	NULL
of	NULL
acute	NULL
lymphoid	NULL
leukemia	NULL
.	NULL

Blood	NULL
Cells	NULL
,	NULL
3	NULL
:	NULL
475-491	NULL
,	NULL
1977	NULL
.	NULL

CANCER	NULL
RESEARCH	NULL
VOL	NULL
.	NULL

40	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1980	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

AAGR	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
Cancer	NULL
Research	NULL
The	NULL
Journal	NULL
of	NULL
Cancer	NULL
Research	NULL
(	NULL
1916-1930	NULL
)	NULL
|	NULL
The	NULL
American	NULL
Journal	NULL
of	NULL
Cancer	NULL
(	NULL
1931-1940	NULL
)	NULL
Heterogeneity	NULL
of	NULL
the	NULL
in	NULL
Vitro	NULL
Responses	NULL
to	NULL
Glucocorticoids	NULL
in	NULL
Acute	NULL
Leukemia	NULL
F.	NULL
Homo	NULL
,	NULL
D.	NULL
Duval	NULL
,	NULL
J.	NULL
L.	NULL
Harousseau	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Cancer	NULL
Res	NULL
1980	NULL
;	NULL
40:2601-2608	NULL
.	NULL

Updated	NULL
version	NULL
Access	NULL
the	NULL
most	NULL
recent	NULL
version	NULL
of	NULL
this	NULL
article	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//cancerres.aacrjournals.org/content/40/7/2601	NULL
E-mail	NULL
alerts	NULL
Reprints	NULL
and	NULL
Subscriptions	NULL
Permissions	NULL
Sign	NULL
up	NULL
to	NULL
receive	NULL
free	NULL
email-alerts	NULL
related	NULL
to	NULL
this	NULL
article	NULL
or	NULL
journal	NULL
.	NULL

To	NULL
order	NULL
reprints	NULL
of	NULL
this	NULL
article	NULL
or	NULL
to	NULL
subscribe	NULL
to	NULL
the	NULL
journal	NULL
,	NULL
contact	NULL
the	NULL
AACR	NULL
Publications	NULL
Department	NULL
at	NULL
pubs	NULL
@	NULL
aacr.org	NULL
.	NULL

To	NULL
request	NULL
permission	NULL
to	NULL
re-use	NULL
all	NULL
or	NULL
part	NULL
of	NULL
this	NULL
article	NULL
,	NULL
use	NULL
this	NULL
link	NULL
http	NULL
:	NULL
//cancerres.aacrjournals.org/content/40/7/2601	NULL
.	NULL

Click	NULL
on	NULL
``	NULL
Request	NULL
Permissions	NULL
``	NULL
which	NULL
will	NULL
take	NULL
you	NULL
to	NULL
the	NULL
Copyright	NULL
Clearance	NULL
Center	NULL
's	NULL
(	NULL
CCC	NULL
)	NULL
Rightslink	NULL
site	NULL
.	NULL

Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1980	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

